US20230338753A1 - Methods of using focused acoustic waves for non-invasive sonodynamic therapy - Google Patents
Methods of using focused acoustic waves for non-invasive sonodynamic therapy Download PDFInfo
- Publication number
- US20230338753A1 US20230338753A1 US18/214,421 US202318214421A US2023338753A1 US 20230338753 A1 US20230338753 A1 US 20230338753A1 US 202318214421 A US202318214421 A US 202318214421A US 2023338753 A1 US2023338753 A1 US 2023338753A1
- Authority
- US
- United States
- Prior art keywords
- patient
- acoustic waves
- sonodynamic therapy
- transducer
- invasive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009214 sonodynamic therapy Methods 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000008878 coupling Effects 0.000 claims abstract description 12
- 238000010168 coupling process Methods 0.000 claims abstract description 12
- 238000005859 coupling reaction Methods 0.000 claims abstract description 12
- 210000003625 skull Anatomy 0.000 claims description 93
- 238000002604 ultrasonography Methods 0.000 claims description 45
- 238000001816 cooling Methods 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000004556 brain Anatomy 0.000 claims description 25
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 19
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 19
- -1 porphyrin compound Chemical class 0.000 claims description 16
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 16
- 208000005017 glioblastoma Diseases 0.000 claims description 11
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 10
- 231100000433 cytotoxic Toxicity 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 abstract description 53
- 206010028980 Neoplasm Diseases 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 46
- 210000003128 head Anatomy 0.000 description 40
- 230000005540 biological transmission Effects 0.000 description 34
- 238000010586 diagram Methods 0.000 description 29
- 230000008569 process Effects 0.000 description 27
- 238000012545 processing Methods 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 24
- 150000003278 haem Chemical class 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 238000005393 sonoluminescence Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 238000009825 accumulation Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000003111 delayed effect Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 229950003776 protoporphyrin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000050051 Chelone glabra Species 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 102000003875 Ferrochelatase Human genes 0.000 description 2
- 108010057394 Ferrochelatase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 230000005457 Black-body radiation Effects 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 1
- 101710133393 POU domain, class 3, transcription factor 3 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000013529 heat transfer fluid Substances 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000004861 thermometry Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/0085—Devices for generating hot or cold treatment fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
- B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
- B06B1/00—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency
- B06B1/02—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy
- B06B1/0207—Driving circuits
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
- B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
- B06B1/00—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency
- B06B1/02—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy
- B06B1/06—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
- B06B1/0607—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction using multiple elements
- B06B1/0622—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction using multiple elements on one surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00084—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320068—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic
- A61B2017/320069—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic for ablating tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00023—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids closed, i.e. without wound contact by the fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00434—Neural system
- A61B2018/00446—Brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00714—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0054—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water
- A61F2007/0056—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water for cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
- A61F2007/0096—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator with a thermometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0282—Compresses or poultices for effecting heating or cooling for particular medical treatments or effects
- A61F2007/0288—Compresses or poultices for effecting heating or cooling for particular medical treatments or effects during operations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/003—Destruction of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
- A61N2007/006—Lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0073—Ultrasound therapy using multiple frequencies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0082—Scanning transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0095—Beam steering by modifying an excitation signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N2007/027—Localised ultrasound hyperthermia with multiple foci created simultaneously
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
- B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
- B06B2201/00—Indexing scheme associated with B06B1/0207 for details covered by B06B1/0207 but not provided for in any of its subgroups
- B06B2201/70—Specific application
- B06B2201/76—Medical, dental
Definitions
- This disclosure relates to a broadly applicable technology platform for treating lesions using sonodynamic therapy. More particularly, this disclosure relates to devices, systems, and methods for treating tumors and cancer in body parts using sonodynamic therapy.
- Sonodynamic therapy is a proposed form of treatment using drugs that only become cytotoxic upon exposure to ultrasound. Since ultrasound can be focused into small tissue volumes within the body, this method provides a potential means of localizing treatment and reducing the risk of side effects elsewhere in the body. In this respect it is similar to photodynamic therapy, which uses light for drug activation, and there are several drugs that have been shown to be sensitive to both light and sound.
- a potential key advantage of sonodynamic over photodynamic therapy is the much greater tissue depth that can be reached non-invasively by ultrasound compared to light.
- the drug is a sonosensitizing agent (i.e., sonosensitizer) that preferentially accumulates in the cells of the lesions.
- Sonosensitizers initiate a cytotoxic response in target tissues when exposed to ultrasonic energy.
- sonodynamic therapy drugs or “sonosensitisers” Upon activation by the ultrasonic energy, sonodynamic therapy drugs or “sonosensitisers” produce reactive oxygen species (ROS) that generate the cytotoxic effect.
- ROS reactive oxygen species
- the detailed mechanisms of ROS production are not fully understood but several studies have indicated that acoustic cavitation and the associated thermal, chemical or luminescence phenomena may be involved. They can be used alone or in concert with other sono sensitizers, many of which are approved by the Food and Drug Administration (FDA) for use in neurosurgical diagnostic imaging or treatment of tumors throughout the body.
- FDA Food and Drug Administration
- sonodynamic therapy is the ability to treat a lesion, such as a region in an organ or tissue which has suffered damage through injury or disease, such as a wound, ulcer, abscess, or tumor, with levels of ultrasound that are safe for healthy tissue yet lethal to cells within the lesion harboring a sonosensitizer.
- lesions could be treated directly with a catheter placed in situ using a relatively simple procedure mimicking a biopsy.
- Getting an acoustic wave to be consistent and omnidirectional from a small, needle-like catheter device can present technical challenges in some instances.
- the small diameter of the catheter device, necessary for a minimally invasive procedure can limit the aperture size for any element acoustically radiating axially from the tip. Because of this, the field strength can fall off due to spherical divergence. Even the acoustic wave emitted radially from a sufficiently long transducer falls off cylindrically.
- the acoustic wave near the catheter device may need to be relatively high to have acoustic intensities sufficient for activating a sonosensitizer several centimeters away from the catheter device. These higher intensities near the catheter device may even be enough to cause indiscriminant cell death close to the catheter device, creating a necrotic region around the catheter device. If this “necrotic” region of the catheter device were unavoidable, it can limit the locations of the body where the catheter device can be placed and limit the number of patients eligible for treatment.
- High intensity focused ultrasound provides a non-invasive treatment of lesions using intensities of 500 W/cm 2 to 20000 W/cm 2 precisely pinpointed over just a few cubic millimeters to cause thermal ablation of the tissue.
- HIFU techniques can ablate tissue non-invasively by heating the tissue to temperatures above 42° C. causing necrotic cell death.
- the levels of ultrasound used in this procedure are by design lethal to all cells within the ultrasound focus, therefore with this approach it is not possible to provide broad coverage that discriminates between healthy tissue and diseased tissue.
- Additional challenges of non-invasive techniques employing sonodynamic therapy can be the strong attenuation and reflection of acoustic pressure from the patient's body, in particular the skull when treating soft tissue and bone.
- the impedance mismatch between water/skin and bone is significant resulting in strong reflection at the skin-bone and the bone-brain interfaces.
- the attenuation coefficient of the skull can also be quite high resulting in losses due to absorption and scattering within the skull.
- the following disclosure describes various sonodynamic therapy apparatuses, systems, and methods for a completely non-invasive treatment that can penetrate deep into the body.
- An illustrative non-invasive approach to sonodynamic therapy includes locating several ultrasound transducers or a single transducer with multiple elements outside of the body part used to transmit acoustic waves through the skin and into the body part
- the size of the transducers can allow incident acoustic waves to be roughly planar and not suffer from as much divergent loss as cylindrical or spherical divergence.
- the acoustic waves generated by several ultrasound transducers or several elements of a single transducer converge to allow the wavefronts to constructively interfere.
- the total surface area of acoustic elements can allow the energy transmission to split up amongst many elements instead of requiring all the energy to come from a single element.
- Such a system can improve the experience of patients. It is non-invasive, so the cost and risk of surgery, infection, and hemorrhage is eliminated as well as the cost and complexity of health care is greatly reduced. Preparing a patient for treatment can take significantly less time. The therapy may last 30 minutes to an hour in a non-surgical clinic setting, such as an oncology clinic. A single practitioner can monitor several patients at the same time. Because the risk of the device is lower, this may open the door to more frequent treatment, early treatment within a disease progression, and treatment of less lethal disease.
- the illustrative non-invasive apparatuses, systems, and methods described in the following disclosure can use relatively low acoustic intensity over a broader treatment area versus conventional methods.
- the illustrative non-invasive techniques discussed hereinbelow produce non-thermally ablative temporal average acoustic intensities in the ranges of about 0.1 to about 50 W/cm 2 , or about 0.2 to about 20 W/cm 2 , or about 0.5 W/cm 2 to about 8.0 W/cm 2 over most or all of the body part being treated for lesions such as a region in an organ or tissue which has suffered damage through injury or disease, such as a wound, ulcer, abscess, or tumor.
- the terms “about” and “generally,” with respect to values means within 10% of the least significant unit. For example, “about 0.1” means between 0.09 and 0.11.
- FIG. 1 is a perspective view of a transcranial sonodynamic therapy device with a shell having multiple transducers and a cooling system placed over the head of a patient, according to at least one aspect of the present disclosure.
- FIG. 2 is a perspective view of a transcranial sonodynamic therapy device with multiple transducers and a cooling system placed over the head of a patient, according to at least one aspect of the present disclosure.
- FIG. 3 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the multiple transducers, according to at least one aspect of the present disclosure.
- FIG. 4 is a schematic view of a transducer with a lens defining a concave surface, according to at least one aspect of the present disclosure.
- FIG. 5 is a schematic view of a transducer with a lens defining a convex surface, according to at least one aspect of the present disclosure.
- FIG. 6 is a schematic view of a transducer with multiple elements that can be individually energized to produce a variety of acoustic waves, according to at least one aspect of the present disclosure.
- FIG. 7 is a bottom view of a transducer having an internal element surrounded by concentric rings, according to at least one aspect of the present disclosure.
- FIG. 8 is a bottom view of a transducer having internal elements arranged in 2-dimensional (2D) grid array, according to at least one aspect of the present disclosure.
- FIG. 9 is a diagram of two acoustic ultrasonic pulses without delay that constructively interfere, according to at least one aspect of the present disclosure.
- FIG. 10 is a diagram of a pulse packet made of a sine wave signal modulated by a Gaussian pulse signal, according to at least one aspect of the present disclosure.
- FIG. 11 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the skull and brain of the patient and multiple transducers with one transducer emitting energy into the brain of the patient, according to at least one aspect of the present disclosure.
- FIG. 12 is a chart showing an intensity transmission ratio across multiple frequencies, according to at least one aspect of the present disclosure.
- FIG. 13 A is a chart showing a transmission and reflection ratio at 1 MHz versus skull thickness in millimeters, according to at least one aspect of the present disclosure.
- FIG. 13 B is a chart showing a transmission and reflection ratio at 1 MHz versus skull thickness in wavelengths, according to at least one aspect of the present disclosure.
- FIG. 14 A is a chart showing an intensity transmission ratio as a function of frequency, according to at least one aspect of the present disclosure.
- FIG. 14 B is a chart showing a reflection ratio as a function of frequency, according to at least one aspect of the present disclosure.
- FIG. 15 is a chart showing the field strength of a planar wave into a multi-tissue skull model, according to at least one aspect of the present disclosure.
- FIG. 16 is a chart showing the energy absorbed ratio of a freshly excised human skull at multiple frequencies, according to at least one aspect of the present disclosure.
- FIG. 17 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the multiple transducers and a full view of the cooling system, according to at least one aspect of the present disclosure.
- FIG. 18 is perspective view of a patient interface, according to at least one aspect of the present disclosure.
- FIG. 19 is a chart showing the relative sensitivity plot of an infrared (IR) temperature sensor, according to at least one aspect of the present disclosure.
- FIG. 20 is a block diagram of a general non-invasive sonodynamic therapy system, according to at least one aspect of the present disclosure.
- FIG. 21 is an illustrative diagram of the sonodynamic therapy system shown in FIG. 18 , according to at least one aspect of the present disclosure.
- FIG. 22 is a schematic diagram of the sonodynamic therapy system shown in FIGS. 18 and 19 , according to at least one aspect of the present disclosure.
- FIG. 23 is a schematic diagram of a sonodynamic therapy system with separate transmitting and receiving transducers, according to at least one aspect of the present disclosure.
- FIG. 24 is a schematic diagram of a sonodynamic therapy system with a single transmitting and receiving transducer, according to at least one aspect of the present disclosure.
- FIG. 25 is an overview of a sonodynamic therapy process, according to at least one aspect of the present disclosure.
- FIG. 26 is a diagram of a cancer cell illustrating the initial stage of selective accumulation of a sensitizer, according to at least one aspect of the present disclosure.
- FIG. 27 is a diagram of the cancer cell illustrating the increased selective accumulation of a sensitizer, according to at least one aspect of the present disclosure.
- FIG. 28 is a diagram of the cancer cell shown in FIGS. 24 and 25 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure.
- FIG. 29 is a diagram illustrating the process of sonoluminescence, according to at least one aspect of the present disclosure.
- FIG. 30 is a schematic diagram of a cancer cell illustrating the selective accumulation of a sensitizer, according to at least one aspect of the present disclosure.
- FIG. 31 is a schematic diagram of the cancer cell shown in FIG. 28 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure.
- the present disclosure is directed to a system for sonodynamic therapy.
- the system comprises a transducer, a patient interface to acoustically couple the transducer to a patient, and a controller coupled to the transducer.
- the controller is configured to generate an electrical drive signal from a set of modulated acoustic wave parameters, modulate the drive signal, and drive the transducer with the modulated drive signal at a frequency to produce a modulated acoustic wave to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- the present disclosure is directed to another system for sonodynamic therapy.
- the system comprises a first transducer, a second transducer, and a controller coupled to the first and second transducers.
- the controller is configured to generate a first electrical drive signal from a set of modulated acoustic wave parameters, generate a second electrical drive signal from the set of modulated acoustic wave parameters, drive the first transducer at the first electrical drive signal to produce a first acoustic wave, and drive the second transducer at the second electrical drive signal to produce a second acoustic wave.
- the first and second acoustic waves are combinable to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- the present disclosure is directed to yet another system for sonodynamic therapy.
- the system comprises a plurality of transducers and a controller coupled to the plurality of transducers.
- the controller is configured to generate a plurality of electrical drive signals from a set of modulated acoustic wave parameters and drive the plurality of transducers at the plurality of electrical drive signals to produce a plurality of modulated acoustic waves.
- the plurality of modulated acoustic waves are combinable to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- the following description provides illustrative examples of applications of non-invasive sonodynamic therapy techniques to treat tumors within the brain. It will be appreciated, however, that such techniques can be applied to treat tumors within other body parts.
- FIG. 1 human skulls can vary by gender and anatomical location.
- the non-invasive sonodynamic therapy device 100 may comprise a shell 110 with transducers 150 that can provide predictable and consistent insonication despite these variations.
- the shell 110 may comprise a rigid material. Known relative positions of the transducers 150 can allow for imaging of the head, even in low resolution with large transducers 150 .
- the illustrated aspect may require a mobile stand to hold in position on the patient while he/she waits in a seated or supine position.
- the rigid shell 110 may be a lightweight helmet that can be worn by the patient during treatment, allowing for predictable placement of the transducers 150 with little infrastructure requirements.
- the non-invasive sonodynamic therapy device 100 may comprise a flexible shell 110 (e.g., a helmet) with transducers 150 placed over a liquid-cooled skull cap 160 as described further elsewhere herein, requiring little infrastructure to support the array of transducers 150 . It may be possible for the patient to don the skull cap 160 and shell 110 in any chair while he/she waits for treatment to complete.
- the lightweight design may minimize neck pain from the patient holding up his/her head for extended periods with the weight of the transducers 150 and cooling cap.
- the flexible shell 110 can conform to the shape of each skull. Such a device may account for subtle variations between treatments depending on the shape of each patient's head curving some transducers 150 more inward or outward.
- the non-invasive sonodynamic therapy device 100 may comprise rigid or flexible patches with several transducers 150 that can be removably applied to the head. Such an aspect may require clinicians to apply each patch individually. Having separate patches can allow for some treatment flexibility without requiring each transducer 150 to be planned and placed individually. An illustrative non-invasive sonodynamic therapy device 100 may minimize sores caused by adhering patches to the head repeatedly, which may be a particular concern for older and sicker patients.
- the non-invasive sonodynamic therapy device 100 may comprise patches with single transducers 150 that can be removable applied to the head. Individual transducers 150 can provide the most treatment flexibility. Such a device may require a detailed process for planning to apply and applying the transducers 150 . Given the additional flexibility, the illustrative non-invasive sonodynamic therapy device 100 may accommodate for greater usability risk.
- the size and shape of the transducers 150 may vary across various disclosed aspects.
- larger transducers 150 which produce directional acoustic waves, may be used.
- Large transducers 150 can be made less directional by applying to each transducer 150 an acoustic lens that bends the acoustic waves as described further elsewhere herein.
- smaller transducers 150 which can radiate more broadly than larger transducers 150 , can be used.
- Such small transducers 150 can have a greater ability to image or beam steer as an array.
- FIG. 3 is a partial cutaway view of a transcranial sonodynamic therapy device 100 placed over the head of a patient showing a partial view of the multiple transducers 150 , according to at least one aspect of the present disclosure.
- the acoustic wave 200 can be defocused to minimize the spatial variation of the acoustic wave intensity in the brain.
- the size and shape of the transducers 150 may defocus or focus each transducer 150 .
- focused refers to an acoustic wavefront that is more convergent than a wavefront produced by a transducer 150 with a planar emitting surface
- defocused refers to an acoustic wavefront that is more divergent than a wavefront produced by a transducer 150 with a planar emitting surface.
- a lens needs to be concave or convex to make a wave more divergent depends on whether the acoustic wave is transitioning from a region of low acoustic impedance to a region of high acoustic impedance or the acoustic wave is transitioning from a region of high acoustic impedance to a region of low acoustic impedance.
- a lens is made of a material with higher acoustic impedance than the target medium (water/tissue)
- the acoustic wave originates in the high-impedance material and transitions to the low-acoustic impedance target medium. If the lens is concave, the lens will “focus” the acoustic wave to make it more convergent. If the lens is convex, the lens will “defocus” the acoustic wave to make it more divergent.
- FIG. 4 is a schematic view of a transducer 150 with a lens 302 defining a concave surface 304 , according to at least one aspect of the present disclosure.
- the lens 302 may be acoustically coupled to the transducer 150 or may be formed integrally therewith.
- the lens 302 is made of a material with higher acoustic impedance than the target medium (water/tissue) such that the acoustic wave 306 originates in the high-impedance material and transitions to the low-acoustic impedance target medium causing the acoustic wave 306 “focus” or converge to the target tissue.
- FIG. 5 is a schematic view of a transducer 150 with a lens 308 defining a convex surface 310 , according to at least one aspect of the present disclosure.
- the lens 308 may be acoustically coupled to the transducer 150 or may be formed integrally therewith.
- the lens 308 is made of a material with higher acoustic impedance than the target medium (water/tissue). Accordingly, an acoustic wave 312 originates in the high-impedance material and transitions to the low-acoustic impedance target medium causing the acoustic wave 312 to “defocus” or diverge to the target tissue.
- the focus of the transducers 150 also depends on the material and shape of the lens (not shown). Using a lens 302 , 308 allows the transducers 150 to be flat, which may minimize manufacturing costs. Both the lens 302 with the concave surface 304 and the lens 310 with the convex surface 310 may be configured to produce a fixed focus.
- FIG. 6 is a schematic view of a transducer 150 with multiple elements 150 a - 150 h that can be individually energized to produce a variety of acoustic waves, according to at least one aspect of the present disclosure.
- multiple transducer elements 150 a - 150 h can be arranged in an array to produce converging, diverging, or planar, acoustic waves.
- the transducer elements 150 a - 150 h can be activated in a predetermined sequence to selectively generate convergent/divergent/planar acoustic waves, such as, for example, the convergent acoustic wave 314 , shown in FIG.
- the outer transducer elements 150 a, 150 h are initially energized and after a time delay the adjacent inner transducer elements 150 b, 150 g are energized. The next adjacent inner transducer elements 150 c, 150 f are energized after a second time delay. Finally, the inner transducer elements 150 d, 150 e are energized after a third time delay. This pattern can be repeated to generate the converging acoustic wave 314 .
- the first, second, and third time delays may be equal or may vary in order to generate more complex acoustic waves.
- the transducer elements 150 a - 150 h may be energized in reverse order to produce a diverging acoustic wave using equal or different time delays.
- the transducer elements 150 a - 150 h can be interchangeably configured to transmit or receive acoustic waves.
- FIG. 7 is a bottom view of a transducer 400 having an internal element 420 surrounded by concentric rings 410 , according to at least one aspect of the present disclosure.
- Each transducer 150 can be adapted and configured to produce an acoustic wave with variable focus.
- One way to accomplish this can be with each transducer 400 having concentric rings 410 (e.g., an annular array) as shown in FIG. 7 .
- Each concentric ring 410 can be driven with a different signal.
- the signal going to the inner element 420 may be progressively more delayed than the outer of the concentric ring 410 .
- the acoustic waves from each concentric ring 410 may converge at a point.
- the acoustic wave at the outer of the concentric rings 410 may be progressively more delayed relative to the inner element 420 .
- One way to make an annular array can be with concentric rings 410 of equal area.
- the annular array may comprise concentric rings 410 of unequal area.
- FIG. 8 is a bottom view of a transducer comprising internal elements 452 arranged in 2-dimensional (2D) grid array 450 , according to at least one aspect of the present disclosure.
- Each internal element 452 of the 2D grid transducer array 450 can be driven with a different signal.
- a converging acoustic wave e.g., “focus”
- the signal applied to the inner element 454 may be progressively more delayed than the signal applied to the outer elements of the 2D grid transducer array 450 .
- the acoustic wave produced by the outer elements 452 may be progressively more delayed relative to the inner element 454 .
- each of the internal elements 452 of the 2D grid transducer array 450 may define an equal area.
- each of the internal elements 452 of the 2D grid transducer 450 array may define an unequal area.
- the transducer 150 , 400 , 450 may be implemented as a single transducer comprising multiple piezoelectric elements with acoustically/electrically-independent sections arranged in an array. In other aspects, the transducer 150 , 400 , 450 may be implemented as different transducers working in a coordinated manner. There is little or no distinction from a physics perspective between a single transducer with multiple elements and different transducers working in coordination. The elements of an array can be sized on the order of a wavelength. In one aspect, the transducer 150 , 400 , 450 may be implemented as a single transducer comprising a plurality of elements implemented as an annular array as shown in FIG. 7 or as a grid array as shown in FIG. 8 . In another aspect, the transducer 150 , 400 , 450 may be implemented as a plurality of individual transducers.
- each of the transducers 150 , 400 , 450 shown in FIGS. 4 - 8 , or elements thereof are non-invasive and may be implemented in a suitable size and shape to fit on the body part of the patient. Also, the individual number and arrangement of transducer elements may be selected to fit on the body part of the patient.
- the transducer 150 , 400 , 450 , or elements thereof may be made of piezoelectric or single crystal material which converts electrical energy to ultrasonic energy. The transducer 150 , 400 , 450 also can receive back ultrasonic energy and converts it to electrical energy.
- Each of the transducers 150 , 400 , 450 , or elements thereof may be adaptively focused to produce acoustic waves by collaborative transducer performance.
- each of the transducers 150 , 400 , 450 , or elements thereof may be selectively controlled to operate either as a transmitter or as a receiver by a controller as described hereinbelow.
- each of the transducers 150 400 , 450 , or elements thereof may be selectively energized and actuated to produce convergent, divergent, or planar acoustic waves as discussed in more detail in the following description.
- the acoustic wave produced by the transducer 150 , 400 , 450 may be defined by vergence—a measure of the curvature of the acoustic wavefront
- vergence a measure of the curvature of the acoustic wavefront
- a negative vergence is when the acoustic wavefront propagates away from a point (i.e., divergence).
- a positive vergence is when the acoustic wavefront propagates towards a point (i.e., convergence).
- a zero vergence is a planar acoustic wavefront that does not converge or diverge.
- Vergence is a property of a single acoustic wavefront.
- a single converging/diverging acoustic wavefront may be produced by multiple elements of a transducer 150 , 400 , 450 (e.g., a transducer comprising an annular array 400 or a grid array 450 ).
- the acoustic wave produced by the transducer 150 , 400 , 450 may be characterized by phase and/or delay.
- the phase and/or delay may be employed to measure a relative shift in time between two acoustic waves.
- the phase is the amount of time shifted between two acoustic waves relative to the period of the two acoustic waves (e.g., measured in degrees or radians).
- the delay is a measure of the amount of time shifted between two acoustic waves (e.g., measured in milliseconds). Delay and phase are often used interchangeably.
- delay may be described in units of degrees or radians, it is well understood that “delay” is an abbreviation for “phase delay.”
- phase delay For a single acoustic wave pulse, it is clearer to discuss delay between the peaks of two acoustic wave pulses in terms of time because a phase shift requires a periodic signal. For repeating acoustic waves, the relative delay is often measured terms of phase. For continuous, periodic acoustic waves, delaying an integer number of periods should have no effect because, by definition, a periodic signal exhibits symmetry over full period shifts.
- the acoustic wave can be delayed by an integer number of cycles.
- the beginning and end of the wave packet will have some edge effect when one signal begins/ends before the other. In the middle of the two wave packets, there will be no effect (provided the signals still overlap).
- the transducers 150 , 400 , 450 may be adapted and configured to produce a “focused” acoustic wave by producing a convergent acoustic wave that converges to a point.
- the transducers 150 , 400 , 450 may be adapted and configured to produce a “defocused” acoustic wave, e.g., a divergent acoustic wave.
- the transducers 150 , 400 , 450 may be adapted and configured to produce a planar acoustic wave (e.g., zero vergence) where the acoustic wave is neither “defocused” nor “defocused.”
- the transducers 150 , 400 , 450 may be driven at ultrasonic frequencies in a range of about 20.00 kHz to about 12.00 MHz. More particularly, the transducers 150 , 400 , 450 may be driven at ultrasonic frequencies in a range of about 650.00 kHz to about 2.00 MHz. In a preferred range, the transducers 150 , 400 , 450 may be driven at ultrasonic frequencies in a range of about 900.00 kHz to about 1.20 MHz and more preferably at about 1.06 MHz.
- FIG. 9 is a diagram 470 of two acoustic ultrasonic pulses 472 , 474 without delay that constructively interfere, according to at least one aspect of the present disclosure.
- the transducers 150 , 400 , 450 may be adapted and configured to produce a “focused” acoustic wave by coordinating time between multiple acoustic wavefronts and producing wavefronts that constructively interfere.
- the coordination of acoustic wavefronts is independent of the vergence of the acoustic wavefronts.
- the point at which the wavefronts focus can be adjusted by delaying one signal relative to another.
- the diagram 470 shown in FIG. 9 shows two pulses 472 , 474 produced without any relative delay.
- the two pulses 472 , 474 constructively interfere when they reach the center and may be said to be focused in the center to produce a combined pulse 474 . If the acoustic pulse 472 on the left is delayed relative to the acoustic pulse 474 on the right, the two pulses 472 , 474 would meet at a point left of center, thus shifting the point of constructive interference to the left of center. Likewise, if the acoustic pulse 474 on the right is delayed relative to the acoustic pulse 474 on the right, the two pulses 472 , 474 would meet at a point to the right of center, thus shifting the point of constructive interference to the right of center.
- a mixture of convergent/divergent/planar acoustic waves may be timed to meet and constructively interfere at one location.
- a divergent acoustic wave may be timed to meet and destructively interfere at one location.
- Control of the converging and diverging wavefronts produced by the transducers 150 , 400 , 450 can be taken into account as part of pretreatment planning. Based on inputs from the pretreatment planning processes the controller can adaptively modulate the transducers 150 , 400 , 450 such that the acoustic wavefronts coordinate to preferentially target a desired treatment region.
- a digital imaging and communications (DICOM) image from a computerized tomography (CT) or other imaging source could be an input to the device controller to generate customized modulation pattern that optimizes the treatment region for a particular patient.
- the pretreatment planning could include selection of a preferred transducer type or arrangement of transducer types that will produce an optimized treatment region for a particular disease state.
- the patient interface may come in various arrangements that can be selected during pretreatment planning to coordinate the transducer(s) in preferred arrangement for treatment.
- “Defocused” acoustic waves may be measured based on the volume of tissue treated according to the number of nodes and antinodes. A histogram of intensities or pressures over some volume may be employed to measure “defocused” acoustic waves. In one aspect, a dose-volume histogram may be employed in planning sonodynamic therapy. Alternatively, a cumulative histogram may be employed.
- FIG. 10 is a diagram of an acoustic pulse packet 480 made of a repeating signal modulated by a Gaussian pulse signal, according to at least one aspect of the present disclosure.
- the acoustic wave generated by the transducer 150 , 400 , 450 may be amplitude modulated.
- the acoustic pulse packet 480 may be produced by modulating a repeating signal, such as a sine wave, with a Gaussian pulse where the repeating signal is independent from the Gaussian pulse.
- the transducer 150 , 400 , 450 is driven by the modulated signal, it produces an acoustic pressure pulse 482 where the amplitude varies according to the envelope 484 , which is in the form of the Gaussian pulse.
- the repeating signal is a sine wave
- the repeating signal may take many forms.
- the repeating signal may be modulated by rectangular pulses, triangular pulses, or pulses of a predefined mathematical shape.
- a repeating signal may be pulse-width modulated, duty-cycle modulated, phase modulated, frequency modulated, randomized phase modulated, or may be modulated using any suitable modulation technique to produce a desired acoustic pulse packet
- the repeating signal may include inter or intra pulse variations.
- FIG. 11 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the skull 510 and brain of the patient and multiple transducers 150 with one transducer emitting energy 200 into the brain of the patient, according to at least one aspect of the present disclosure. It can be possible to take measurements or get a rough image of the skull 510 as shown in FIG. 11 . This can be facilitated if the transducers 150 are fixed to a rigid shell and their relative positions and orientations are known. Rough measurements can be used to adjust the treatment algorithm by measured parameters such as skull thickness, “t.” Each transducer 150 may send out an acoustic pulse and listen for an echo. The echoes can be used for a quick estimate of the skull thickness, “t,” under each transducer 150 .
- the sonodynamic therapy device may be adapted and configured to the couple to the body of the patient.
- the focus of each transducer 150 can be set beforehand with treatment planning.
- the transducers 150 can adjust their focus automatically based on temperature readings of the head or based on skull thickness, “t,” measurements.
- the amplitude of the electrical drive signal driving the transducers 150 can be controlled or modulated. In some cases, it can be beneficial to modulate the electrical drive signal driving the transducers 150 based on the temperature of the head or other body part being treated. For example, if the temperature sensors are detecting a sharp rise in temperature, the amplitude of the transducers 150 can be decreased, shut off for a period, or the duty cycle can be decreased. By modulating the intensity of the acoustic pulses, the temporal average acoustic intensity may be regulated to activate the sensitizer while maintaining the temperature of the tumor cells below a temperature (e.g., below 42° C.) capable of causing thermal damage to the cell and in some circumstances necrotic cell death.
- a temperature e.g., below 42° C.
- sonodynamic therapy can function at a variety of different frequencies. Each frequency can transmit through a skull 510 efficiently with certain thicknesses of skulls. Using a variety of frequencies can allow a non-invasive sonodynamic therapy device 100 to operate on a broad range of skull thicknesses, “t.”
- the frequency of each transducer 150 can be selected manually or automatically.
- the transducers 150 may be driven at ultrasonic frequencies in a range of about 20.00 kHz to about 12.00 MHz. More particularly, the transducers 150 may be driven at ultrasonic frequencies in a range of about 650.00 kHz to about 2.00 MHz. In a preferred range, the transducers 150 may be driven at ultrasonic frequencies in a range of about 900.00 kHz to about 1.20 MHz and more preferably at about 1.06 MHz.
- the frequencies can be preselected by a physician. The frequencies can be selected based on a measurement of head anatomy (e.g. skull thickness, “t”).
- each transducer 150 can send out a sequence of pulses to measure the thickness of the skull 510 closest to it. Based on the result of the skull thickness, “t,” measurement, an algorithm can be used to select frequencies from a set of frequencies or from a range of frequencies that may be best suited for the skull thickness, “t,” and energize the transducers 150 accordingly.
- the size and shape of the transducers 150 may vary across various disclosed aspects.
- larger transducers 150 which may have directional acoustic waves, may be used.
- Large transducers 150 can be made less directional by applying to each transducer 150 an acoustic lens that bends the acoustic waves as described further elsewhere herein.
- smaller transducers 150 which can radiate more broadly than larger transducers 150 , can be used.
- Such small transducers 150 can have a greater ability to image or beam steer as an array.
- the acoustic wave 200 can be defocused to minimize the spatial variation of the acoustic wave intensity in the brain as shown in FIG. 4 .
- the size and shape of the transducers 150 may defocus or focus each transducer 150 .
- Defocused transducers can be formed using a transducer 150 with a convex emitting surface 310 as seen in FIG. 5 .
- design of the transducers can focus the sound from each transducer 150 using a concave emitting surface 304 with a center of curvature where the sound can focus.
- an array of transducers 150 a - 150 h can be used to generate acoustic waves that are convergent, divergent, or more complex.
- Each transducer 150 can cycle through several frequencies so that at least one of the frequencies can transmit nearly optimally for the given skull thickness, “t.” Each transducer 150 may also sweep continuously from one frequency to another. A frequency can be pre-selected for each transducer 150 based on the thickness of skull 510 nearest to it (e.g., during treatment planning by the physician). Prior to treatment, each transducer 150 can transmit test signals and monitor the reflected sound to automatically determine which frequency or frequencies can work best for that one of the transducers 150 . The test signals can be used to measure the skull thickness, “t,” directly by measuring delays in pulse echoes, or they can be used to detect the relative amount of reflected acoustic energy.
- Each transducer 150 can be made up of a broad-spectrum ultrasonic transducer or can be made up of several smaller transducers (e.g., piezo-electric elements as shown in FIGS. 6 - 8 ) designed to work at particular frequencies. Each transducer 150 can have an element specifically designed to monitor the waves reflected from the head. In the case where the transducers 150 are made of several smaller transducers 150 , while one transducer 150 is transmitting sound, the other transducers 150 may be used to monitor the incoming acoustic pulses.
- frequencies that work with sonodynamic therapy a subset of frequencies can be selected to best cover a range of common skull thicknesses, “t.”
- Frequencies that share many common factors e.g., harmonics such a 1 MHz and 2 MHz
- Frequencies without many or any common factors may make for good choices for frequencies because the transmission peaks can occur at different skull thicknesses.
- FIG. 12 is a chart 700 showing an intensity transmission ratio across multiple frequencies, according to at least one aspect of the present disclosure.
- each skull thickness can have at least one frequency that can transmit 75% or more of its energy. This can be accomplished with frequencies between 898 kHz and 1.107 MHz, a range of only 0.2 MHz
- Transmission of sound through an absorbing layer of tissue may not monotonically decrease as function of thickness. Instead, transmission can be enhanced when the thickness of the skull is a multiple of half the wavelength of the sound in that layer. Similarly, when the thickness of the skull is an odd multiple of quarter wavelengths (halfway between A/2 multiples), the transmission can be reduced.
- FIG. 13 A is a chart 720 showing an intensity transmission and pressure reflection ratio at 1 MHz versus skull thickness in millimeters and FIG. 13 B is a chart 730 showing a transmission and reflection ratio at 1 MHz versus skull thickness in wavelengths, according to at least one aspect of the present disclosure.
- FIGS. 13 A and 13 B the transmission of a 1 MHz soundwave through various skull thicknesses.
- FIG. 7 A shows the skull thickness in millimeters
- FIG. 13 B shows the skull thickness in multiples of wavelength of the intensity transmission ratio 722 and the reflection ratio 724 .
- the intensity transmission ratio 722 can reach a peak whenever the skull is a multiple of a half wavelength.
- the ratio of sound reflected shown as the reflection ration 724 can be at a minimum whenever the skull is a multiple of a half wavelength.
- the intensity transmission ratio 722 and the pressure reflection ratio 724 can be functions of both the skull thickness and the frequency.
- FIG. 14 A is a chart 740 showing an intensity transmission ratio 722 as a function of frequency and
- FIG. 14 B is a chart 750 showing a reflection ratio 724 as a function of frequency, according to at least one aspect of the present disclosure.
- To the right of the chart 740 in FIG. 14 A is a scale 742 of the intensity transmission ratio 722 ranging from 0.0 to 1.0 and the right of the chart 750 in FIG. 14 B is a scale of the reflection ratio 724 ranging from ⁇ 1.0 to +1.0.
- FIGS. 14 A and 14 B show how the intensity transmission ratio 722 and the reflection ratio 724 change with skull thickness and frequency.
- Negative reflection ratios can be achieved wherever peak transmission may be occurring. Negative reflection ratios can indicate that the reflected wave can be phase shifted 180° relative to the incident wave.
- the intensity transmission ratio 722 has a maximum ratio 744 of about 1.0 and a minimum ratio 746 of about 0.4, which is consistent with the maximum/minimum ratios shown in charts 720 , 730 in FIGS. 13 A and 13 B .
- the chart 750 shown in FIG. 14 B shows that the reflection ratio 724 has a minimum ratio 754 of about 0.0 and a maximum ratio 756 of about 0.8, which is consistent with maximum/minimum ratios shown in the charts 720 , 730 in FIGS. 13 A and 13 B .
- Frequencies that are different by an irrational number may make good choices because they can have peak transmissions at different thicknesses.
- the golden ratio e.g., the “most irrational number” may be useful in selecting frequencies. It may not be sufficient for selected frequencies' transmission to avoid peaking at the same skull thickness, “t.”
- the device can select the best frequency (e.g., the greatest transmission ratio) at each skull thickness, “t,” then to get optimal coverage across many skull thicknesses, “t,” with a limited number of frequencies can mean to maximize the average transmission ratio of the best frequency across the selected skull thicknesses, “t,” or to maximize the minimum transmission ratio of the best frequency within the selected skull thicknesses, “t.”
- the best frequency e.g., the greatest transmission ratio
- Hair on the patient's head may need to be shaved or shortened to allow for efficient transmission of sound into the brain. Some aspects may allow the hair to remain untouched.
- a comb-like structure can be able to pass through hair to contact the skull in many locations to transmit sound.
- the hair may also be wet and matted down to allow for the sound to transmit relatively unimpeded.
- FIG. 15 is a chart 760 showing the field strength of a planar wave 762 into a multi-tissue skull model, according to at least one aspect of the present disclosure.
- the skull may absorb a large proportion of the ultrasonic energy in a short distance.
- the insertion loss 764 (the amount of energy that can be lost by adding the skull into the acoustic wave 200 ) can be centered around 12 dB. Every additional 3 dB worth of loss can correspond to approximately half of the energy being reduced.
- a 12 dB loss can be equivalent to a sixteenth of the energy introduced at the surface of the skin being left at the surface of the skull. Because of this, the skull may heat up during transcranial sonodynamic therapy.
- Table 1 is a summary of the parameters that can be used in the model of the skull.
- the skin can be assumed to be 2.5 mm thick, and the skull can be assumed to be around 6.8 mm thick.
- FIG. 15 shows the acoustic intensity in terms of field strength (dB) as a function of distance within the head model.
- the insertion loss 764 highlighted region emphasizes the jumps of energy lost at the interfaces and steep attenuation within the skull.
- the model uses an average of various human skull thicknesses.
- the thickness of the “frontal, parietal and occipital bones were (in mm) 6.58, 5.37 and 7.56, respectively, for the male; and 7.48, 5.58 and 8.17, respectively, for the female.”
- human skulls vary considerably by gender and anatomical location.
- the model can represent an average amount of attenuation, but thicker sections of skull can have a greater amount of attenuation. In general, every additional 2.7 mm worth of skull can increase the attenuation by 3 dB (a factor of 2).
- This model can be based on a simple plane wave model impinging on planar layers of tissue.
- Each layer of tissue can be assumed to be homogenous and uniform thickness.
- the effect of the acoustic wavelength ( ⁇ ) matching with various thicknesses of skull are ignored in this model. It can also be assumed that all reflected waves are lost and do not reenter the brain.
- Pichardo et al. investigated the transmission of ultrasound through freshly excised human skulls at various frequencies. They report the ratio of absorbed energy for seven skulls at several locations at the frequencies of 0.270, 0.836, and 1.402 MHz. While they did not measure the energy lost at 1 MHz specifically, their study allows interpolation and estimation that the insertion loss can be centered around 12 dB. Their study also can confirm that the insertion loss can be expected to vary by skull and anatomical location.
- FIG. 16 is a chart 770 showing the energy absorbed ratio 772 of a freshly excised human skull at multiple frequencies, according to at least one aspect of the present disclosure.
- Pinton et al. also measured the attenuation at 1 MHz of nine points along an 8 mm thick section of skull bone and found an insertion loss of 12.6 ⁇ 1.33 dB (higher loss due to a thick skull section).
- Both the simplified head model and measurements taken from different laboratories agree that the insertion loss (the amount of energy lost by adding the skull into the model) can be centered around 12 dB (a factor of 16) with considerable variation.
- the energy lost as the sound passes through the skull may be converted into heat primarily in the skull.
- the temperature of the skull can begin to heat up and, over time, heat can disperse to nearby tissue. Most of the heating can originate at the outer surface of the skull and disperse into the skin and other layers of bone. Above certain intensities, the blood can be unable to transport enough heat away, and the temperature in the bone and skin can rise to unsafe levels. Adding more transducers into the system can decrease the intensity at which this threshold can be reached because the blood can be warmed by each successive transducer it passes and lose its ability to absorb additional heat from the tissue.
- cooling can be used to reduce the consequences of heating.
- FIG. 17 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the multiple transducers 150 and a full view of a cooling system 600 , according to at least one aspect of the present disclosure.
- the cooling system 600 shown in FIG. 17 may be implemented to keep the temperature of the skull and surrounding tissue within safe levels.
- a cooling layer e.g., of water
- the cooling layer can be made of a flexible membrane or balloon that can conform to each patient's head.
- a large cooling layer may be reusable and, thus, may require cleaning between each use.
- the cooling system 600 can be made of a flexible cavity (not shown) with an inlet and an outlet for a coolant such as water to circulate.
- a coolant such as water to circulate.
- the head of the patient can be inserted into a concave shape (e.g., a “bowl”) with an elastic opening.
- the elastic opening can seal against the head of the patient. Water can fill up the space between the patient's head and the bowl.
- water can be circulated to keep the temperature of the water from rising.
- One advantage of such a system can be that water in the cooling system 600 can be in direct contact with the patient's head. The air around the patient's hair can be removed by the water, which may help couple the ultrasound transducers 150 to the patient's head.
- FIG. 18 is perspective view of a patient interface 650 , according to at least one aspect of the present disclosure.
- the cooling system 600 can be a cap 160 with cooling channels 630 distributed throughout.
- the cap 160 can have one long loop of cooling channels 630 , or it can have several independent loops.
- a system with several cooling loops can be connected to a single inlet and outlet tube via a manifold, or they can be controlled independently.
- Water or other heat transfer fluid can be circulated through the cooling channels 630 to exchange heat generated either by the transducers 150 , the patient's body, or a combination thereof.
- each patch may have its own cooling channels 630 .
- the cooling channels 630 can be water-filled tubes that may be larger and heavier than the wires going to the transducers 150 .
- the number of unique cooling channels 630 can be optimized to avoid excessive weight in the cooling layer.
- the effect of heating can be readily monitored with temperature sensors and reduced with the fluid cooling system 600 .
- a layer of cool, degassed water between the ultrasonic transducers 150 and the head can serve a dual function of coupling the head to the transducers 150 and controlling the temperature of the skull.
- the head Prior to any insonication, the head can be cooled for several minutes by a constant flow of cool water.
- the temperature of the skull can be monitored continuously, which can modulate the treatment over the entire skull, or it can individually modulate each transducer 150 .
- a safe treatment algorithm can be devised with intermittent treatment and continuous cooling with a margin of safety for all patients. Intermittent treatment can also be more effective than the same effective treatment time done continuously due to the rate limiting step of oxygen diffusion around the sonosensitizer.
- thermometry of deep-seated tissues. Any surface measurements of temperature may need to be insulated from the cooling layer of water to prevent the probe from being dominated by the cooling layer's effect.
- the temperature of the patient's head may need to monitored. If temperature sensors (not shown) are simply placed between the cooling layer and the head, the temperature sensor can be reading some combination of the head temperature and the cooling layer temperature.
- the temperature sensor can be isolated from the temperature of the cooling layer.
- a layer of insulation can be placed between the cooling layer and each temperature sensor. In such instances, the area around each temperature sensor can receive less or no cooling.
- FIG. 19 is a chart 800 showing the relative sensitivity plot 802 of an infrared (IR) temperature sensor, according to at least one aspect of the present disclosure.
- a temperature probe (not shown) that measures only in one direction (e.g., unidirectional) can be utilized.
- An example of a unidirectional temperature sensor can be an IR temperature sensor.
- IR temperature sensors measure the infrared light being emitted by an object via black body radiation.
- IR temperature sensors accept radiation coming in from a small range of angles (e.g., an acceptance cone).
- one or more IR sensors can be oriented so that the cone of acceptance of each sensor can be facing the patient's head.
- One or more methods above can be combined to accurately monitor the temperature of the patient's head.
- FIG. 20 is a block diagram of a general non-invasive sonodynamic therapy system 900 , according to at least one aspect of the present disclosure.
- the non-invasive sonodynamic therapy system 900 comprises a controller 902 coupled to an ultrasonic transducer array 904 to control the operation of the ultrasonic transducer array 904 to generate a suitable ultrasonic acoustic wave.
- the ultrasonic transducer array 904 is coupled to a patient interface 906 to couple the ultrasonic acoustic wave produced by the ultrasonic transducer array 904 to a sensitizer 908 that accumulates in tumor cells within the patient's body. Through a process called sonoluminescence, the ultrasonic acoustic wave produces light that activates the sensitizer 908 and causes necrosis of the tumor cells.
- Sonodynamic therapy treatment employs a sensitizer 908 drug that only become cytotoxic upon exposure to ultrasound.
- sonodynamic therapy drugs generally referred to as “sonosensitisers” produce ROS that generate the cytotoxic effect to kill the tumor cell.
- Sonodynamic therapy provides much greater tissue depth that can be reached non-invasively by ultrasound as compared to in over photodynamic therapy.
- the sensitizer 908 may comprise 5-aminolevulinic acid (5-ALA) among other sensitizers 908 such as hematoporphyrin, Rose Bengal, curcumin, titanium nanoparticles, chlorine e6, and any combinations thereof.
- the sonodynamic process may comprise injecting microbubbles into the tumor tissue to “seed” cavitation, enabling bubble to accumulate in the tumor tissue, or injecting a drug to oxygenate tumor tissue.
- the sonodynamic therapy process described herein may be combined with one or more other adjuvant therapies such as chemotherapy, immunotherapy, radiotherapy, and/or HIFU.
- the non-invasive sonodynamic therapy system 900 may be employed to treat a variety of tumors and to treat the area around the tumor cavity, whether malignant or nonmalignant.
- the area around the tumor cavity includes cells that cause the recurrence and eventual mortality in malignant tumors.
- the non-invasive sonodynamic therapy system 900 may be configured to treat prostate cancer via trans-rectal ultrasound sonodynamic therapy and cervical cancer via trans-vaginal ultrasound sonodynamic therapy, for example.
- the controller 902 may be configured to drive the ultrasonic transducer array 904 .
- the controller 902 may be configured to execute one or more than one control algorithm setup/reflection assessment and tune the drive frequency to skull thickness. This can be done automatically.
- the control algorithm may be configured to pulse or control the “duty cycle” of the ultrasonic transducer array 904 drive waveform to generate high temporal peak acoustic intensity of ultrasonic acoustic waves with low temporal average acoustic intensity sufficient to activate the sensitizer 908 while preventing thermal necrotic death of the tumor cells in the treatment region.
- the control algorithm may be configured to generate packets of waves that are delayed to overlap the tumor.
- the control algorithm may be configured to control the intensity of the ultrasonic acoustic wave.
- control algorithm may be configured to control the phase of the ultrasonic acoustic wave.
- control algorithm may be configured to randomize the phase of the ultrasonic acoustic wave. Modulating acoustic waves with phase randomization promotes broad consistent coverage across a treatment region where acoustic wavefronts constructively combine at varying pseudo random locations within the treatment region, rather than the exact same location with each cycle. This control scheme provides a more homogeneous treatment region to aid broad consistent treatment coverage and avoid sub therapeutic dead spots in the treatment region. Phase randomization provides additional benefit in adapting to the treatment environment. Repeating the exact same excitation pattern in some types of acoustical environments could lead to the potential for standing waves to form. Standing waves are inherently dangerous as they can deliver unintended treatment energy to the patient. A controller scheme that provides phase randomization of the acoustic waveform can mitigate the risks of repetitive excitation that can lead to standing waves.
- a feedback loop may be provided back to the controller 902 to adjust the drive signal to the ultrasonic transducer array 904 based on in situ variables such as tissue depth, tissue thickness, tissue volume, skull thickness, temperature, among other variables.
- the controller 902 may be located in an ultrasonic generator or may be located elsewhere.
- in situ variables may include a disease state or an inner body location. The disease state may include alternative treatment ultrasonic transducer probe that is driven differently for each disease state. Examples of feedback loops are described hereinbelow in connection with FIGS. 22 - 24 .
- the ultrasonic transducer array 904 may be configured according to the transducers 150 , 400 , 450 described hereinabove. In various aspects, however, the form factor of the ultrasonic transducer array 904 may be configured to couple ultrasonic acoustic waves in various locations on the patient's body other than the head. For example, the ultrasonic transducer array 904 may be configured to generate ultrasound that activates a sensitizer 908 to treat tumors in the brain, such as glioblastoma, lung, breast, stomach, liver, pancreas, intestines, rectum, colon, vagina, testes, among others, whether the tumors are malignant or nonmalignant.
- a sensitizer 908 to treat tumors in the brain, such as glioblastoma, lung, breast, stomach, liver, pancreas, intestines, rectum, colon, vagina, testes, among others, whether the tumors are malignant or nonmalignant.
- the ultrasonic transducer array 904 is non-invasive and produces ultrasonic acoustic waves capable of reaching the target tumor cells non-invasively.
- the ultrasonic transducer array 904 may be configured as annular array, 2D grid array, a linear array, and the like, to generate an adaptively focused ultrasonic acoustic wave optimized based on in situ variables such as tissue depth, tissue thickness, tissue volume, skull thickness, among other variables.
- the ultrasonic transducer array 904 may adaptively focus or adjust the ultrasonic acoustic wave based on pretreatment planning or safety.
- the controller 902 executes a control algorithm to generate selectively convergent/divergent ultrasonic acoustic waves including adaptive focus for collaborative transducer performance.
- the ultrasonic acoustic array 904 may be configured to perform transmitter and receiver functions that may be controlled by the controller 902 .
- the ultrasonic transducer array 904 is coupled to the patient interface 906 to facilitate acoustic coupling of the ultrasonic vibrations generated by the ultrasonic transducer array 904 into the patient's body.
- the patient interface 906 like the ultrasonic transducer array 904 , is non-invasive.
- the patient interface 906 may be configured to remove air between the ultrasonic transducer array 904 and the patient's body to facilitate acoustic coupling.
- the patient interface 906 may be configured to remove excess heat from the patient's body.
- the patient interface 906 may comprise a variety of sensors, such as a temperature sensor, for example. Signals from such sensors may be provided as feedback to the controller 902 (see FIG.
- Such feedback may be employed to control the ultrasonic transducer array 904 to generate a desired ultrasonic acoustic wave.
- the patient interface 906 also may include gel or hydrogel layers to improve the acoustical coupling between the ultrasonic transducer array 904 and the patient's body.
- the patient interface 1022 may be configured to locally apply cooling.
- the patient interface 1022 may be configured for sensor feedback to the processing unit 902 .
- the non-invasive sonodynamic therapy system 900 comprises a sensitizer 908 that may be absorbed by the tumor cells.
- Sonodynamic therapy requires the combination of the sensitizer 908 , such as a sensitizing drug, ultrasound generated by the ultrasonic transducer array 904 coupled into the patient's body by the patient interface 906 , and molecular oxygen. Although these components are non-toxic individually, when combined together, a cytotoxic ROS is generated to kill the tumor cells. Sonodynamic therapy may be configured to provide penetration of ultrasound through the patient's body and can be used to treat a wide array of deep and hard to access tumors.
- FIG. 21 is an illustrative diagram 1000 of the sonodynamic therapy system 900 shown in FIG. 20 , according to at least one aspect of the present disclosure.
- the sonodynamic therapy system 900 comprises a controller 902 that may be located in an ultrasonic generator 1002 .
- the ultrasonic generator 1002 comprises a controller 1012 , a user interface 1004 , a foot switch 1006 for activating the controller 1012 , and a cap or helmet 1008 that is placed over the head of the patient.
- a cable 1010 that carries electrical signals to and from the ultrasonic transducer array 904 couples the transducer array 904 and the ultrasonic generator 1002 .
- the ultrasonic transducer array 904 comprises an array of ultrasonic transducers 150 , 400 , 450 placed over a patient interface 906 such as the skull cap 160 .
- the ultrasonic generator 1002 drives the ultrasonic transducers 150 , 400 , 450 to generate an ultrasonic acoustic wave 200 that is coupled into the body of the patient to excite the sensitizer 908 ingested by the patient and absorbed by the tumor cells.
- the controller 1012 shapes the acoustic wave to achieve a convergent, divergent, or planar acoustic wave, or more complex acoustic waves.
- the sensitizer 908 may comprise and ALA sensitizing drug that is activated in a sonoluminescence process, for example.
- FIG. 22 is a schematic diagram 1100 of the sonodynamic therapy system 900 shown in FIGS. 20 and 21 , according to at least one aspect of the present disclosure.
- the controller 902 of the sonodynamic therapy system 900 comprises a user interface 1102 coupled to a processing unit 1104 and configured to receive input from a user and providing output to the user.
- the processing unit 1104 may be a processor or microcontroller coupled to a memory, a control circuit, or a combination thereof.
- the ultrasonic transducer array 904 comprises one or more than one ultrasonic transducer 1114 and one or more than one monitoring ultrasonic transducer 1116 . It will be appreciated that the same ultrasonic transducer element may be configured to implement an ultrasonic transmitter function as well as a receiver function (see FIG.
- the patient interface 906 comprises one or more than one temperature sensors 1118 to monitor the temperature of the patient 1122 .
- the patient interface 906 also comprises a cooling system 1120 to reduce the temperature of the patient 1122 .
- the patient interface 906 may be configured to eliminate air gaps between the transducer 1114 and the patient 1122 to enable acoustical coupling.
- the processing unit 1104 is configured to execute machine executable instructions to implement various control algorithms as previously described.
- the processing unit 1104 may comprise a memory to store such machine executable instructions and processing engines to execute the control algorithms.
- the processing unit 1104 also may be implemented in hardware with digital and analog electronic components.
- the processing unit 1104 is coupled to a multiplexing system 1112 and a power source 1106 suitable for driving the ultrasonic transducers 1114 .
- the ultrasonic transducers 1114 are coupled to the body of the patient 1122 to activate the sensitizer 908 administered to the patient 1122 .
- at least one sonosensitizer 908 agent may be configured for preferential accumulation in selective tissue of the patient 1122 .
- Monitoring ultrasonic transducers 1116 monitor acoustic feedback from the patient 1122 and generate signals that are provided as feedback to the processing unit 1104 via an analog-to-digital converter 1110 (ADC).
- ADC analog-to-digital converter
- a power monitoring device 1108 monitors the power source 1106 and provides feedback to the processing unit 1104 through the ADC 1110 .
- the processing unit 1104 controls the ultrasonic transducer drive signals based on the acoustic feedback signal and/or the power monitoring signal to achieve a desired ultrasonic acoustic wave inside the body of the patient 1122 .
- at least one ultrasonic transducer 1114 is configured to output selectively convergent and divergent acoustic waves.
- the transducer 1114 may be configured in an annular array or a grid array.
- the transducer 1114 may be configured with multiple electrodes.
- the transducer 1114 may be configured to receive reflected acoustical signals.
- the processing unit 1104 is coupled to the temperature sensors 1118 and receives patient temperature feedback through the ADC 1010 .
- the processing unit 1104 controls the cooling system 1120 based at least in part on the patient temperature feedback signal.
- the processing unit 1102 is configured to produce a pulsed acoustical signal with temporal-average intensity output below 8 W/cm 2 .
- the processing unit 1102 is adapted to apply amplitude-modulated acoustical signals including constructive interference over a plurality of wave cycles.
- the processing unit 1102 further may be configured to output packets of acoustic waves at various delayed sequences to provide diffused tissue coverage.
- the processing unit 1102 may be configured to execute frequency adaptive algorithms to optimize transmission of acoustical signals.
- the processing unit 1102 may be configured to control phased randomization of acoustical signals.
- the present disclosure provides a sonodynamic therapy device comprising a transducer 904 , a patient interface 906 , and a controller 902 adapted to activate a sensitizer 908 within the body of the patient 1122 .
- the transducer 904 may comprise one or more than one transducer 1114 , 1116 where the controller 902 is configured to generate a broadband range of ultrasonic frequencies to drive the transducer 904 and produce divergent, convergent, or planar acoustic waves.
- the patient interface 906 is configured to transmit acoustic waves produced by the transducer(s) 904 into the body of the patient 1122 thus acoustically coupling the transducer(s) 904 to the patient 1122 .
- the patient interface 906 provides a cooling system 1120 to remove any excess heat that builds up in the patient 1122 as a of the coupling acoustic energy to the body of the patient 1122 .
- the patient interface 906 may comprise an integral cooling system 1120 .
- the patient interface 906 may comprise a hydrogel cap filled with gel or a water-filled cap with cooling channels.
- the patient interface 906 comprises one or more than one sensor 1118 to provide feedback to the processing unit 1104 of the controller 902 .
- the sensors 1118 my include, for example, temperature sensors, optical temperature sensors to measure temperature in a particular direction, acoustic sensors, which may include the same transducers 904 used for transmitting acoustic signals.
- the patient interface 906 may be configured to remove air from the patient interface 906 to improve acoustic coupling between the transducer 904 and the body of the patient 1122 .
- the patient interface 906 may be configured to cool the patient 1122 .
- the patient interface 906 may be configured to cool the transducers 904 , for example, to keep the transducers at the same temperature to achieve frequency stability.
- the patient interface 906 may be adapted and configured to fit various patient anatomies.
- the patient interface 906 may be adapted and configured to fit patient anatomies for sonodynamic therapy specifically adapted to treat tumors located in the brain, lung, breast, stomach, liver, pancreas, intestines, rectum, colon, vagina, testes, among others, for example.
- a sonodynamic therapy device may be adapted to wrap around the torso or limb of the patient and/or employed to treat osteosarcoma into the bone.
- the controller 902 may be adapted to detect either the patient interface 906 or the sonodynamic therapy device such as the transducer 904 or patient interface 906 and select a treatment algorithm to produce acoustic waves optimized for treating the various tumors.
- the transducer 904 or patient interface 906 may be identified using identification (ID) circuits 1115 , 1119 comprising a single-wire serial EEPROM, for example.
- ID circuit 1115 , 1119 EEPROM may contain both a preprogrammed unique serial number and memory sections. Any or all of the memory sections can be permanently locked by the end-equipment manufacturer to allow tracking of products and identifying attachments.
- Other identification techniques may include detecting the impedance of the transducer 904 or patient interface 906 and associating the impedance with a treatment algorithm.
- the controller 902 is configured to generate electrical drive signals to actuate one or more than one ultrasonic transducer 904 to produce an acoustic wave to activate a sensitizer 908 located within the body of the patient 1122 .
- the electrical drive signals generated by the controller 902 may actuate the one or more than one ultrasonic transducer 904 to produce acoustic waves of varying intensities, amplitudes, or frequencies.
- the acoustic waves may be amplitude modulated, frequency modulated, phase modulated, continuous, discontinuous, pulsed, randomized, or combinations thereof.
- the acoustic waves my be produced in a packet of wave cycles, where the number of cycles per packet may be predetermined to achieve a desired outcome that is different from a focused ultrasound pulse, for example.
- the controller 902 is configured to generate a frequency modulation signal to produce a frequency-modulated acoustic wave.
- the controller may be configured to generate an intra or inter pulse variation signal that can be used to reduce standing acoustic waves.
- the controller 902 is configured to apply an amplitude-modulated acoustic ultrasound signal which constructively interferes over a plurality of wave cycles.
- the intensity of each of the plurality of acoustic waves remain within a safe range wherein the ultrasound energy carried by each of the plurality of acoustic waves is safe to the tissue of the patient 1122 , such as the brain or other body part.
- the controller 902 may be configured to drive the transducer 904 to generate an amplitude-modulated acoustic wave which produces a constructive wavefront.
- the sonodynamic therapy device comprises one transducer 904 and the controller 902 may be configured to generate a drive signal to actuate the transducer 904 to produce a long acoustic ultrasonic wave packet
- the controller 902 may be configured to generate a drive signal to actuate the transducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a Gaussian pulse (see FIG. 10 for example).
- the controller 902 may be configured to generate a drive signal to actuate the transducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a rectangular pulse.
- the controller 902 may be configured to generate a drive signal to actuate the transducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a triangular pulse.
- the ultrasonic acoustic wave packet may comprise intra or inter wave packet variation.
- the controller 902 may be configured to generate a drive signal to actuate the transducer 904 to produce an acoustic ultrasonic pulse.
- the acoustic wavefronts of the ultrasonic pulse may either converge to focus the ultrasonic energy to a specific region or diverge to spread the ultrasonic energy to a larger region.
- the sonodynamic therapy device comprises two or more transducers 904 and the controller 902 may be configured to generate a drive signal to actuate the two or more transducers 904 to produce acoustic ultrasonic pulses where the individual wavefronts, whether converging or diverging, will meet at the same location at the same time to focus the ultrasonic energy.
- the controller 902 may adapt the frequency drive for each transducer 904 .
- FIG. 23 is a schematic diagram of a sonodynamic therapy system 920 with a separate transmitter transducer 930 and receiver transducer 934 , according to at least one aspect of the present disclosure.
- the sonodynamic therapy system 920 comprises a system controller 922 to control a signal generator 924 to generate an electrical signal to drive the transmitter transducer 930 .
- the electrical signal is amplified by an amplifier 926 and the drive signal is coupled to the transmitter transducer 930 by a matching network 928 to maximize power transferred to the transmitter transducer 930 .
- the transmitter transducer 930 transmits an acoustic wave into tissue 932 (e.g., lesions) in the treatment region.
- a receiver transducer 934 detects acoustic waves emitted by the tissue 932 .
- the output of the receiver transducer 934 is a weak electrical signal that is provided to an electronic pre-amplifier 936 that converts the weak electrical signal into an output signal strong enough to be noise-tolerant and strong enough for further processing such as filtering by a filter 938 .
- the output of the filter 938 is provided to an analog-to-digital converter 940 (ADC) that provides a feedback signal to the system controller 922 in digital form.
- ADC analog-to-digital converter 940
- the system controller 922 can adjust the drive signal applied to the transmitter transducer 930 .
- the adjustment may include adjusting the modulation, strength, frequency, phase, or randomization, of the drive signal, or any combinations thereof.
- the feedback signal may represent tissue depth, tissue thickness, tissue volume, skull thickness, temperature, distance to the treatment region, or a combination thereof.
- FIG. 24 is a schematic diagram of a sonodynamic therapy system 950 with a single transmitting and receiving transducer 962 , according to at least one aspect of the present disclosure.
- the sonodynamic therapy system 950 comprises a system controller 952 to control a signal generator 954 to generate an electrical signal to drive the transducer 962 in transmitter mode.
- the electrical signal is amplified by an amplifier 956 and is applied to a transmitter/receiver (T/R) switch 958 .
- T/R switch 958 couples the drive signal to the transducer 962 via a matching network 960 to optimize power transferred to the transducer 962 .
- the transducer 962 transmits an acoustic wave into tissue 964 (e.g., lesions) in the treatment region.
- tissue 964 e.g., lesions
- the transducer 962 detects acoustic waves emitted by the tissue 964 .
- the output of the transducer 962 is a weak electrical signal that is coupled to the T/R switch 958 by the matching network 960 .
- the T/R switch 958 provides the weak electrical signal to an electronic pre-amplifier 966 that converts the weak electrical signal into an output signal strong enough to be noise-tolerant and strong enough for further processing such as filtering by a filter 968 .
- the output of the filter 968 is provided to an ADC 970 that provides a feedback signal to the system controller 952 in digital form.
- the system controller 952 can adjust the drive signal applied to the transducer 962 in transmitter mode.
- the adjustment may include adjusting the modulation, strength, frequency, phase, or randomization, of the drive signal, or any combinations thereof.
- the feedback signal may represent tissue depth, tissue thickness, skull thickness, temperature, distance to the treatment region, or a combination thereof.
- FIG. 25 is an overview of a sonodynamic therapy process 1200 , according to at least one aspect of the present disclosure.
- a sonodynamic sensitizer 908 as described herein, and dons an ultrasonic transducer array 904 comprising a plurality of ultrasonic transducers 150 .
- the sonodynamic sensitizer 908 may be administered orally or through other natural orifices, by injection, intravenously, topically, or other suitable technique.
- the sonodynamic sensitizer 908 accumulates in tumor cells 1206 .
- an ultrasound acoustic wave 1210 generated by the ultrasonic generator 1002 activates the sonodynamic sensitizer 908 .
- the sonodynamic sensitizer 908 instigates a sequence of death of a tumor cell 1206 .
- FIG. 26 is a diagram 1300 of a tumor cell 1206 illustrating the initial stage of selective accumulation of a sensitizer 908 , according to at least one aspect of the present disclosure.
- the sensitizer 908 is absorbed 1302 into the mitochondria 1304 of the cancer cell 1206 .
- the patient is administered 5-ALA, pro drug sensitizer 908 , orally, which puts the heme 1306 biosynthesis pathway 1316 into overdrive.
- the body's natural feedback mechanism prevents the production of too much heme 1306 .
- Heme 1306 will result in lower activity of the aminolevulinic acid synthase (ALAS) enzyme which produces 5-ALA endogenously.
- ALAS aminolevulinic acid synthase
- protoporphyrin IX 1308 (PpIX) accumulates preferentially in many types of cancer cells 1206 including glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- PpIX 1308 is a catalyst that converts dissolved molecular oxygen into ROS by absorbing photons.
- Protoporphyrin IX 1308 is in the same class of molecules as chlorophyll (i.e., porphyrins), and is capable of converting light into chemical energy.
- FIG. 27 is a diagram 1320 of the cancer cell 1206 illustrating the increased selective accumulation 1322 of the sensitizer 908 , according to at least one aspect of the present disclosure.
- the PpIX 1308 is an active compound and the second to last intermediate product in the heme 1306 biosynthesis pathway 1316 .
- the accumulation of PpIX 1308 in the cancer cell 1206 mitochondria 1304 is due to increased accumulation 1322 of the 5-ALA sensitizer 908 and reduced conversion of PpIX 1308 into heme 1306 (reduced expression of ferrochelatase).
- FIG. 28 is a diagram 1330 of the cancer cell 1206 shown in FIGS. 26 and 27 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure.
- the ultrasonic transducer 904 generates an ultrasound acoustic wave 200 that penetrates the cancer cell 1206 and the mitochondria 1304 .
- the ultrasound acoustic wave 200 produces light 1312 through a process called sonoluminescence. Sonoluminescence occurs when the ultrasound acoustic wave 200 collapses fluid bubbles 1332 causing cavitation 1334 and produces light 1312 in the process.
- the production of light 1312 happens far away from the ultrasonic transducer 904 .
- the light 1312 produced through sonoluminescence activates the PpIX 1308 to produce ROS 1336 .
- Sonoluminescence can occur anywhere the intensity of the ultrasound acoustic wave 200 is sufficient, which allows sonodynamic therapy to treat much deeper than photodynamic therapy.
- the ROS 1336 species cause oxidative stress which results in the cancer cell 1206 undergoing programmed cell death 1314 (apoptosis), which is the same as photodynamic therapy.
- FIG. 29 is a diagram 1400 illustrating the sonoluminescence process, according to at least one aspect of the present disclosure.
- the diagram 1400 can be found in Detlef Lohse, Sonoluminescence, Inside a micro-reactor, Nature volume 418, pages 381-383 (2002), which is incorporated herein by reference.
- a gas bubble 1402 expands dramatically, until an increase in sound-wave pressure triggers a collapse of the gas bubble 1402 .
- the temperature inside the gas bubble 1402 soars to over 10,000 K, the gas in the bubble 1402 becomes partly ionized, forming a plasma 1404 .
- recombination of electrons and ions results in light emission 1406 .
- FIG. 30 is a schematic diagram 1500 of a cancer cell 1502 illustrating the selective accumulation of a sensitizer 908 , according to at least one aspect of the present disclosure.
- the 5-ALA sensitizer 908 is systematically administered into the cancer cell 1502 and is absorbed into the mitochondria 1504 of the cancer cell 1502 .
- the 5-ALA sensitizer 908 is administered to the patient orally, which puts the heme 1506 biosynthesis pathway into overdrive.
- the natural feedback mechanism of the patient's body prevents the production of too much heme 1506 .
- Heme 1506 will result in lower activity of the aminolevulinic acid synthase (ALAS) enzyme which produces 5-ALA endogenously.
- ALAS aminolevulinic acid synthase
- heme 1506 biosynthesis keeps producing even though the ALAS enzyme is inactivated.
- PpIX 1508 accumulates preferentially in many types of cancer cells 1502 including glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- the PpIX 1508 is an active compound and the second to last intermediate product in the heme 1506 biosynthesis pathway 1510 .
- the accumulation of PpIX 1508 in the cancer cell 1502 mitochondria 1504 is due to increased uptake of the 5-ALA sensitizer 908 and reduced conversion of PpIX 1508 into heme 1506 reduced expression of ferrochelatase 1512 .
- the PpIX 1508 is a catalyst that converts dissolved molecular oxygen into ROS by absorbing photons.
- Protoporphyrin IX 1508 is in the same class of molecules as chlorophyll (i.e., porphyrins), and is capable of converting light into chemical energy.
- FIG. 31 is a schematic diagram 1600 of the cancer cell 1502 shown in FIG. 30 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure.
- the ultrasonic transducer 904 generates an ultrasound acoustic wave 200 that penetrates the cancer cell 1502 and the mitochondria 1504 .
- the ultrasound acoustic wave 200 produces light 1602 through cavitation 1606 and a process called sonoluminescence 1604 .
- the production of light 1602 happens far away from the ultrasonic transducer 904 .
- the light 1602 produced through sonoluminescence 1604 activates the PpIX 1508 to produce ROS 1608 .
- Sonoluminescence 1604 can occur anywhere the intensity of the ultrasound acoustic wave 200 is sufficient, which allows sonodynamic therapy to treat much deeper than photodynamic therapy.
- the ROS 1608 species cause oxidative stress which results in the cancer cell 1502 undergoing programmed cell death 1610 (apoptosis), which is the same as photodynamic therapy.
- cavitation 1606 The interaction of acoustic waves 200 with an aqueous medium may result in cavitation 1606 .
- Cavitation 1606 involves nucleation, growth, and implosive collapse of gas-filled bubbles, under the appropriate ultrasound conditions.
- inertial cavitation 1606 involves the growth of gas bubbles to a near resonance size and expanding to a maximum before collapsing violently.
- the energy released by this implosion results in temperatures of up to 10,000 K and pressures of up to 81 MPa in the surrounding microenvironment. Such extreme temperatures and pressures at the point of implosion create a sono-chemical reactor.
- Cavitation 1606 generates ROS 1608 in sonodynamic therapy under two mechanisms of action.
- sonoluminescence 1604 This is process upon which light 1602 is generated upon exposure of the cancer cell 1502 energy produced by the acoustic wave 200 .
- Another possible mechanism of action may be pyrolysis. This is a process whereby localized temperature elevation that accompanies inertial cavitation 1606 breaks apart the sensitizer 908 generating free radicals that can react with other endogenous substrates to generate ROS 1608 .
- ROS 1608 plays an important role is SDT, in some aspects sonodynamic therapy may be based on sonomechanical mechanisms. This conclusion was based on their observation that HP-sensitized cells can be sensitive to the acoustic wave 200 at intensities that were shown not to induce inertial cavitation.
- sonodynamic therapy may be carried out using one or more than one sensitizer 908 .
- sensitizers 908 used in sonodynamic therapy may be selected from a variety of compounds. These compounds include, without limitation, porphyrins such as Photofrin, protoporphyrin IX precursor, xanthene-based sensitizers 908 such as Rose Bengal and derivatives thereof, acridine orange, methylene blue, curcumin, hypocrellin, indocyanine green, nanoparticle/microparticle sensitizer conjugates. Additional information on sonodynamic therapy may be found in Treating Cancer With Sonodynamic Therapy: A Review, David Costley et al., pages 107-117, received 17 Oct. 2014, accepted 23 Nov.
- the sonodynamic therapy techniques described in this disclosure may be applied to animals as well as humans.
- the sonodynamic therapy techniques descried in this disclosure may be applied to mammals.
- use of the term “patient” throughout this disclosure is intended to cover humans and animals alike.
- the sonodynamic therapy techniques described in this disclosure may be adapted to other parts of the body. These other parts of the body may be accessed through natural orifice (mouth, nasal cavity, anus, vagina) or minimally invasive processes such as intravascular access.
- the sonodynamic therapy device may be specifically adapted to have a flexible, navigable catheter shaft to reach tumors in specific organs such as liver, stomach, breast, or lungs, for example.
- the sonodynamic therapy device may be adapted to wrap around the torso or limb and may be employed to treat osteosarcoma into the bone.
- the sonodynamic therapy techniques described in this disclosure may be adapted for use with adjuvant therapies.
- the disclosed sonodynamic therapy techniques may be employed in other cancer therapies including chemotherapy, immunotherapy, radiotherapy, HIFU/hyperthermia.
- the disclosed sonodynamic therapy techniques employ additional drugs which increase oxygen in the brain or increase oxygen in a brain tumor to a preferential oxygen concentration to provide an effective sonodynamic therapy.
- the disclosed sonodynamic therapy techniques may employ a sensitizer which is modified or encapsulated to effectively target a tumor.
- the disclosed sonodynamic therapy techniques may deliver 0 2 systematically with nose tubes.
- the disclosed sonodynamic therapy techniques may employ multiple sensitizers in conjunction and may include the introduction of gas bubbles into the tumor to oxygenate the tumor, create more cavitation, and provide a possible contrast mechanism for imaging.
- the sonodynamic therapy techniques described in this disclosure may be adapted for use with ultrasound imaging.
- the process may include the addition of a contrast agent for ultrasound which goes to the tumor.
- processor or processing unit is an electronic circuit which performs operations on some external data source, usually memory or some other data stream.
- the term is used herein to refer to the central processor (central processing unit) in a system or computer systems (especially systems on a chip (SoCs)) that combine a number of specialized “processors.”
- Soc system on a chip or system on chip
- Soc is an integrated circuit (also known as an “IC” or “chip”) that integrates all components of a computer or other electronic systems. It may contain digital, analog, mixed-signal, and often radio-frequency functions-all on a single substrate.
- a Soc integrates a microcontroller (or microprocessor) with advanced peripherals like graphics processing unit (GPU), Wi-Fi module, or coprocessor.
- a Soc may or may not contain built-in memory.
- a microcontroller or controller is a system that integrates a microprocessor with peripheral circuits and memory.
- a microcontroller (or MCU for microcontroller unit) may be implemented as a small computer on a single integrated circuit It may be similar to a Soc; an Soc may include a microcontroller as one of its components.
- a microcontroller may contain one or more core processing units (CPUs) along with memory and programmable input/output peripherals. Program memory in the form of Ferroelectric RAM, NOR flash or OTP ROM is also often included on chip, as well as a small amount of RAM.
- Microcontrollers may be employed for embedded applications, in contrast to the microprocessors used in personal computers or other general purpose applications consisting of various discrete chips.
- controller or microcontroller may be a stand-alone IC or chip device that interfaces with a peripheral device. This may be a link between two parts of a computer or a controller on an external device that manages the operation of (and connection with) that device.
- processors or microcontrollers described herein may be implemented by any single core or multicore processor such as those known under the trade name ARM Cortex by Texas Instruments.
- the processor may be an LM4F230H5QR ARM Cortex-M4F Processor Core, available from Texas Instruments, for example, comprising on-chip memory of 256 KB single-cycle flash memory, or other non-volatile memory, up to 40 MHz, a prefetch buffer to improve performance above 40 MHz, a 32 KB single-cycle serial random access memory (SRAM), internal read-only memory (ROM) loaded with StellarisWare® software, 2 KB electrically erasable programmable read-only memory (EEPROM), one or more pulse width modulation (PWM) modules, one or more quadrature encoder inputs (QEI) analog, one or more 12-bit Analog-to-Digital Converters (ADC) with 12 analog input channels, details of which are available for the product datasheet
- the processor may comprise a safety controller comprising two controller-based families such as TMS570 and RM4x known under the trade name Hercules ARM Cortex R4, also by Texas Instruments.
- the safety controller may be configured specifically for IEC 61508 and ISO 26262 safety critical applications, among others, to provide advanced integrated safety features while delivering scalable performance, connectivity, and memory options.
- a component can refer to a computer-related entity, either hardware, a combination of hardware and software, software, or software in execution, in addition to electro-mechanical devices.
- a component may be, but is not limited to being, a process running on a processor, a processor, an object, an executable, a thread of execution, a program, and/or a computer.
- an application running on computer and the computer can be a component.
- One or more components may reside within a process and/or thread of execution and a component may be localized on one computer and/or distributed between two or more computers.
- the word “exemplary” is used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein as “exemplar” is not necessarily to be construed as preferred or advantageous over other aspects or designs.
- control circuit may be any stand alone or combination electronic circuit such as, for example, a processing unit, processor, microcontroller, microcontroller unit, controller, digital signal processor (DSP), programmable gate array (PGA), field PGA (FPGA), programmable logic device (PLD), system on chip (SoC), application specific integrated circuit (ASIC), graphics processing unit (GPU), and the like.
- DSP digital signal processor
- PGA programmable gate array
- FPGA field PGA
- PLA programmable logic device
- SoC system on chip
- ASIC application specific integrated circuit
- GPU graphics processing unit
- aspects of the present disclosure describe instruction handling and distribution in the context of execution units and logic circuits
- other aspects of the present disclosure can be accomplished by way of data and/or instructions stored on a machine-readable, tangible medium, which when performed by a machine cause the machine to perform functions consistent with at least one aspect.
- associated functions of the present disclosure are embodied in machine-executable instructions. The instructions can be used to cause a general-purpose or special-purpose processor that is programmed with the instructions to perform the steps of the functions described in the present disclosure.
- aspects of the present disclosure may be provided as a computer program product or software which may include a machine or non-transitory computer-readable medium having stored thereon instructions which may be used to program a computer (or other electronic devices) to perform one or more operations according to aspects of the present disclosure.
- functions according to the present disclosure might be performed by specific hardware components that contain fixed-function logic for performing the functions, or by any combination of programmed computer components and fixed-function hardware components.
- a machine-readable medium may include any mechanism for storing or transmitting information in a form readable by a machine (e.g., a computer), but is not limited to, floppy diskettes, optical disks, Compact Disc, Read-Only Memory (CD-ROMs), and magneto-optical disks, Read-Only Memory (ROMs), Random Access Memory (RAM), Erasable Programmable Read-Only Memory (EPROM), Electrically Erasable Programmable Read-Only Memory (EEPROM), magnetic or optical cards, flash memory, or a tangible, machine-readable storage used in the transmission of information over the Internet via electrical, optical, acoustical or other forms of propagated signals (e.g., carrier waves, infrared signals, digital signals, etc.). Accordingly, the non-transi
Abstract
Disclosed are methods of using focused acoustic waves for providing non-invasive sonodynamic therapy. The method includes acoustically coupling an array of piezoelectric transducers to a patient. A controller is configured to generate an electrical drive signal at a frequency selected from a range of frequencies, modulate the drive signal, and drive the transducer with the modulated drive signal at the frequency to produce modulated acoustic waves to produce an average acoustic intensity sufficient to activate a sonosensitizer in a treatment region without damaging healthy cells in the treatment region.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/399,964, filed Aug. 11, 2021, which is a continuation of PCT Application No. PCT/US2020/017983, filed Feb. 12, 2020, and titled NON-INVASIVE SONODYNAMIC THERAPY, which claims priority under 35 U.S.C. § 119 to U.S. Provisional Patent Application No. 62/805,186, filed, Feb. 13, 2019, and titled NON-INVASIVE SONODYNAMIC THERAPY, each of which is hereby incorporated by reference herein in its entirety.
- This disclosure relates to a broadly applicable technology platform for treating lesions using sonodynamic therapy. More particularly, this disclosure relates to devices, systems, and methods for treating tumors and cancer in body parts using sonodynamic therapy.
- Sonodynamic therapy is a proposed form of treatment using drugs that only become cytotoxic upon exposure to ultrasound. Since ultrasound can be focused into small tissue volumes within the body, this method provides a potential means of localizing treatment and reducing the risk of side effects elsewhere in the body. In this respect it is similar to photodynamic therapy, which uses light for drug activation, and there are several drugs that have been shown to be sensitive to both light and sound. A potential key advantage of sonodynamic over photodynamic therapy is the much greater tissue depth that can be reached non-invasively by ultrasound compared to light.
- The drug is a sonosensitizing agent (i.e., sonosensitizer) that preferentially accumulates in the cells of the lesions. Sonosensitizers initiate a cytotoxic response in target tissues when exposed to ultrasonic energy. Upon activation by the ultrasonic energy, sonodynamic therapy drugs or “sonosensitisers” produce reactive oxygen species (ROS) that generate the cytotoxic effect. The detailed mechanisms of ROS production are not fully understood but several studies have indicated that acoustic cavitation and the associated thermal, chemical or luminescence phenomena may be involved. They can be used alone or in concert with other sono sensitizers, many of which are approved by the Food and Drug Administration (FDA) for use in neurosurgical diagnostic imaging or treatment of tumors throughout the body.
- The promise of sonodynamic therapy is the ability to treat a lesion, such as a region in an organ or tissue which has suffered damage through injury or disease, such as a wound, ulcer, abscess, or tumor, with levels of ultrasound that are safe for healthy tissue yet lethal to cells within the lesion harboring a sonosensitizer.
- In a contemplated minimally invasive sonodynamic process, lesions could be treated directly with a catheter placed in situ using a relatively simple procedure mimicking a biopsy. Getting an acoustic wave to be consistent and omnidirectional from a small, needle-like catheter device can present technical challenges in some instances. The small diameter of the catheter device, necessary for a minimally invasive procedure, can limit the aperture size for any element acoustically radiating axially from the tip. Because of this, the field strength can fall off due to spherical divergence. Even the acoustic wave emitted radially from a sufficiently long transducer falls off cylindrically.
- Because of the acoustic intensity falling off due to divergence, the acoustic wave near the catheter device may need to be relatively high to have acoustic intensities sufficient for activating a sonosensitizer several centimeters away from the catheter device. These higher intensities near the catheter device may even be enough to cause indiscriminant cell death close to the catheter device, creating a necrotic region around the catheter device. If this “necrotic” region of the catheter device were unavoidable, it can limit the locations of the body where the catheter device can be placed and limit the number of patients eligible for treatment.
- High intensity focused ultrasound (HIFU) provides a non-invasive treatment of lesions using intensities of 500 W/cm2 to 20000 W/cm2 precisely pinpointed over just a few cubic millimeters to cause thermal ablation of the tissue. HIFU techniques can ablate tissue non-invasively by heating the tissue to temperatures above 42° C. causing necrotic cell death. The levels of ultrasound used in this procedure are by design lethal to all cells within the ultrasound focus, therefore with this approach it is not possible to provide broad coverage that discriminates between healthy tissue and diseased tissue.
- Additional challenges of non-invasive techniques employing sonodynamic therapy can be the strong attenuation and reflection of acoustic pressure from the patient's body, in particular the skull when treating soft tissue and bone. The impedance mismatch between water/skin and bone is significant resulting in strong reflection at the skin-bone and the bone-brain interfaces. The attenuation coefficient of the skull can also be quite high resulting in losses due to absorption and scattering within the skull.
- The following disclosure describes various sonodynamic therapy apparatuses, systems, and methods for a completely non-invasive treatment that can penetrate deep into the body.
- An illustrative non-invasive approach to sonodynamic therapy includes locating several ultrasound transducers or a single transducer with multiple elements outside of the body part used to transmit acoustic waves through the skin and into the body part The size of the transducers can allow incident acoustic waves to be roughly planar and not suffer from as much divergent loss as cylindrical or spherical divergence. In one aspect, the acoustic waves generated by several ultrasound transducers or several elements of a single transducer converge to allow the wavefronts to constructively interfere. Additionally, the total surface area of acoustic elements can allow the energy transmission to split up amongst many elements instead of requiring all the energy to come from a single element.
- Clinically speaking, such a system can improve the experience of patients. It is non-invasive, so the cost and risk of surgery, infection, and hemorrhage is eliminated as well as the cost and complexity of health care is greatly reduced. Preparing a patient for treatment can take significantly less time. The therapy may last 30 minutes to an hour in a non-surgical clinic setting, such as an oncology clinic. A single practitioner can monitor several patients at the same time. Because the risk of the device is lower, this may open the door to more frequent treatment, early treatment within a disease progression, and treatment of less lethal disease.
- The illustrative non-invasive apparatuses, systems, and methods described in the following disclosure can use relatively low acoustic intensity over a broader treatment area versus conventional methods. The illustrative non-invasive techniques discussed hereinbelow produce non-thermally ablative temporal average acoustic intensities in the ranges of about 0.1 to about 50 W/cm2, or about 0.2 to about 20 W/cm2, or about 0.5 W/cm2 to about 8.0 W/cm2 over most or all of the body part being treated for lesions such as a region in an organ or tissue which has suffered damage through injury or disease, such as a wound, ulcer, abscess, or tumor. Unless otherwise specifically stated, the terms “about” and “generally,” with respect to values, means within 10% of the least significant unit. For example, “about 0.1” means between 0.09 and 0.11.
- The following drawings are illustrative of particular aspects of the present disclosure and therefore do not limit the scope of the appended claims” The drawings are intended for use in conjunction with the explanations in the following description. The disclosed aspects will hereinafter be described in conjunction with the appended drawings, wherein like numerals denote like elements.
-
FIG. 1 is a perspective view of a transcranial sonodynamic therapy device with a shell having multiple transducers and a cooling system placed over the head of a patient, according to at least one aspect of the present disclosure. -
FIG. 2 is a perspective view of a transcranial sonodynamic therapy device with multiple transducers and a cooling system placed over the head of a patient, according to at least one aspect of the present disclosure. -
FIG. 3 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the multiple transducers, according to at least one aspect of the present disclosure. -
FIG. 4 is a schematic view of a transducer with a lens defining a concave surface, according to at least one aspect of the present disclosure. -
FIG. 5 is a schematic view of a transducer with a lens defining a convex surface, according to at least one aspect of the present disclosure. -
FIG. 6 is a schematic view of a transducer with multiple elements that can be individually energized to produce a variety of acoustic waves, according to at least one aspect of the present disclosure. -
FIG. 7 is a bottom view of a transducer having an internal element surrounded by concentric rings, according to at least one aspect of the present disclosure. -
FIG. 8 is a bottom view of a transducer having internal elements arranged in 2-dimensional (2D) grid array, according to at least one aspect of the present disclosure. -
FIG. 9 is a diagram of two acoustic ultrasonic pulses without delay that constructively interfere, according to at least one aspect of the present disclosure. -
FIG. 10 is a diagram of a pulse packet made of a sine wave signal modulated by a Gaussian pulse signal, according to at least one aspect of the present disclosure. -
FIG. 11 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the skull and brain of the patient and multiple transducers with one transducer emitting energy into the brain of the patient, according to at least one aspect of the present disclosure. -
FIG. 12 is a chart showing an intensity transmission ratio across multiple frequencies, according to at least one aspect of the present disclosure. -
FIG. 13A is a chart showing a transmission and reflection ratio at 1 MHz versus skull thickness in millimeters, according to at least one aspect of the present disclosure. -
FIG. 13B is a chart showing a transmission and reflection ratio at 1 MHz versus skull thickness in wavelengths, according to at least one aspect of the present disclosure. -
FIG. 14A is a chart showing an intensity transmission ratio as a function of frequency, according to at least one aspect of the present disclosure. -
FIG. 14B is a chart showing a reflection ratio as a function of frequency, according to at least one aspect of the present disclosure. -
FIG. 15 is a chart showing the field strength of a planar wave into a multi-tissue skull model, according to at least one aspect of the present disclosure. -
FIG. 16 is a chart showing the energy absorbed ratio of a freshly excised human skull at multiple frequencies, according to at least one aspect of the present disclosure. -
FIG. 17 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of the multiple transducers and a full view of the cooling system, according to at least one aspect of the present disclosure. -
FIG. 18 is perspective view of a patient interface, according to at least one aspect of the present disclosure. -
FIG. 19 is a chart showing the relative sensitivity plot of an infrared (IR) temperature sensor, according to at least one aspect of the present disclosure. -
FIG. 20 is a block diagram of a general non-invasive sonodynamic therapy system, according to at least one aspect of the present disclosure. -
FIG. 21 is an illustrative diagram of the sonodynamic therapy system shown inFIG. 18 , according to at least one aspect of the present disclosure. -
FIG. 22 is a schematic diagram of the sonodynamic therapy system shown inFIGS. 18 and 19 , according to at least one aspect of the present disclosure. -
FIG. 23 is a schematic diagram of a sonodynamic therapy system with separate transmitting and receiving transducers, according to at least one aspect of the present disclosure. -
FIG. 24 is a schematic diagram of a sonodynamic therapy system with a single transmitting and receiving transducer, according to at least one aspect of the present disclosure. -
FIG. 25 is an overview of a sonodynamic therapy process, according to at least one aspect of the present disclosure. -
FIG. 26 is a diagram of a cancer cell illustrating the initial stage of selective accumulation of a sensitizer, according to at least one aspect of the present disclosure. -
FIG. 27 is a diagram of the cancer cell illustrating the increased selective accumulation of a sensitizer, according to at least one aspect of the present disclosure. -
FIG. 28 is a diagram of the cancer cell shown inFIGS. 24 and 25 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure. -
FIG. 29 is a diagram illustrating the process of sonoluminescence, according to at least one aspect of the present disclosure. -
FIG. 30 is a schematic diagram of a cancer cell illustrating the selective accumulation of a sensitizer, according to at least one aspect of the present disclosure. -
FIG. 31 is a schematic diagram of the cancer cell shown inFIG. 28 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure. - The following detailed description is exemplary in nature and provides some practical illustrations and examples. Those skilled in the art will recognize that many of the noted examples have a variety of suitable alternatives. A number of various exemplary transcranial sonodynamic therapy devices are disclosed herein using the description provided as follows in addition to the accompanying drawings. Each of the aspects disclosed herein can be employed independently or in combination with one or more (e.g., all) of the other aspects disclosed herein.
- Prior to launching into a description of the figures, the present disclosure first turns to a general description of various aspects of non-invasive sonodynamic therapy systems. In one aspect, the present disclosure is directed to a system for sonodynamic therapy. The system comprises a transducer, a patient interface to acoustically couple the transducer to a patient, and a controller coupled to the transducer. The controller is configured to generate an electrical drive signal from a set of modulated acoustic wave parameters, modulate the drive signal, and drive the transducer with the modulated drive signal at a frequency to produce a modulated acoustic wave to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- In another aspect, the present disclosure is directed to another system for sonodynamic therapy. The system comprises a first transducer, a second transducer, and a controller coupled to the first and second transducers. The controller is configured to generate a first electrical drive signal from a set of modulated acoustic wave parameters, generate a second electrical drive signal from the set of modulated acoustic wave parameters, drive the first transducer at the first electrical drive signal to produce a first acoustic wave, and drive the second transducer at the second electrical drive signal to produce a second acoustic wave. The first and second acoustic waves are combinable to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- In yet another aspect, the present disclosure is directed to yet another system for sonodynamic therapy. The system comprises a plurality of transducers and a controller coupled to the plurality of transducers. The controller is configured to generate a plurality of electrical drive signals from a set of modulated acoustic wave parameters and drive the plurality of transducers at the plurality of electrical drive signals to produce a plurality of modulated acoustic waves. The plurality of modulated acoustic waves are combinable to produce an acoustic intensity sufficient to activate a sonosensitizer in a treatment region.
- The following description provides illustrative examples of applications of non-invasive sonodynamic therapy techniques to treat tumors within the brain. It will be appreciated, however, that such techniques can be applied to treat tumors within other body parts. Turning now to
FIG. 1 , human skulls can vary by gender and anatomical location. One aspect of the present disclosure provides a non-invasivesonodynamic therapy device 100 as shown inFIG. 1 . The non-invasivesonodynamic therapy device 100 may comprise ashell 110 withtransducers 150 that can provide predictable and consistent insonication despite these variations. Theshell 110 may comprise a rigid material. Known relative positions of thetransducers 150 can allow for imaging of the head, even in low resolution withlarge transducers 150. The illustrated aspect may require a mobile stand to hold in position on the patient while he/she waits in a seated or supine position. Therigid shell 110 may be a lightweight helmet that can be worn by the patient during treatment, allowing for predictable placement of thetransducers 150 with little infrastructure requirements. - The non-invasive
sonodynamic therapy device 100 may comprise a flexible shell 110 (e.g., a helmet) withtransducers 150 placed over a liquid-cooledskull cap 160 as described further elsewhere herein, requiring little infrastructure to support the array oftransducers 150. It may be possible for the patient to don theskull cap 160 andshell 110 in any chair while he/she waits for treatment to complete. The lightweight design may minimize neck pain from the patient holding up his/her head for extended periods with the weight of thetransducers 150 and cooling cap. Theflexible shell 110 can conform to the shape of each skull. Such a device may account for subtle variations between treatments depending on the shape of each patient's head curving sometransducers 150 more inward or outward. - The non-invasive
sonodynamic therapy device 100 may comprise rigid or flexible patches withseveral transducers 150 that can be removably applied to the head. Such an aspect may require clinicians to apply each patch individually. Having separate patches can allow for some treatment flexibility without requiring eachtransducer 150 to be planned and placed individually. An illustrative non-invasivesonodynamic therapy device 100 may minimize sores caused by adhering patches to the head repeatedly, which may be a particular concern for older and sicker patients. - The non-invasive
sonodynamic therapy device 100 may comprise patches withsingle transducers 150 that can be removable applied to the head.Individual transducers 150 can provide the most treatment flexibility. Such a device may require a detailed process for planning to apply and applying thetransducers 150. Given the additional flexibility, the illustrative non-invasivesonodynamic therapy device 100 may accommodate for greater usability risk. - The size and shape of the
transducers 150, as can be seen inFIG. 2 , may vary across various disclosed aspects. For a cost-effective and simple system,larger transducers 150, which produce directional acoustic waves, may be used.Large transducers 150 can be made less directional by applying to eachtransducer 150 an acoustic lens that bends the acoustic waves as described further elsewhere herein. For a system that can conform to the head,smaller transducers 150, which can radiate more broadly thanlarger transducers 150, can be used. Suchsmall transducers 150 can have a greater ability to image or beam steer as an array. -
FIG. 3 is a partial cutaway view of a transcranialsonodynamic therapy device 100 placed over the head of a patient showing a partial view of themultiple transducers 150, according to at least one aspect of the present disclosure. Instead of focusing anacoustic wave 200 to a small point, theacoustic wave 200 can be defocused to minimize the spatial variation of the acoustic wave intensity in the brain. - The size and shape of the
transducers 150 may defocus or focus eachtransducer 150. As used herein, the term focused refers to an acoustic wavefront that is more convergent than a wavefront produced by atransducer 150 with a planar emitting surface and the term defocused refers to an acoustic wavefront that is more divergent than a wavefront produced by atransducer 150 with a planar emitting surface. Whether a lens needs to be concave or convex to make a wave more divergent depends on whether the acoustic wave is transitioning from a region of low acoustic impedance to a region of high acoustic impedance or the acoustic wave is transitioning from a region of high acoustic impedance to a region of low acoustic impedance. In this regard, if a lens is made of a material with higher acoustic impedance than the target medium (water/tissue), the acoustic wave originates in the high-impedance material and transitions to the low-acoustic impedance target medium. If the lens is concave, the lens will “focus” the acoustic wave to make it more convergent. If the lens is convex, the lens will “defocus” the acoustic wave to make it more divergent. -
FIG. 4 is a schematic view of atransducer 150 with alens 302 defining aconcave surface 304, according to at least one aspect of the present disclosure. Thelens 302 may be acoustically coupled to thetransducer 150 or may be formed integrally therewith. In the illustrated example, thelens 302 is made of a material with higher acoustic impedance than the target medium (water/tissue) such that theacoustic wave 306 originates in the high-impedance material and transitions to the low-acoustic impedance target medium causing theacoustic wave 306 “focus” or converge to the target tissue. -
FIG. 5 is a schematic view of atransducer 150 with alens 308 defining aconvex surface 310, according to at least one aspect of the present disclosure. Thelens 308 may be acoustically coupled to thetransducer 150 or may be formed integrally therewith. In the illustrated example, thelens 308 is made of a material with higher acoustic impedance than the target medium (water/tissue). Accordingly, anacoustic wave 312 originates in the high-impedance material and transitions to the low-acoustic impedance target medium causing theacoustic wave 312 to “defocus” or diverge to the target tissue. - The focus of the
transducers 150 also depends on the material and shape of the lens (not shown). Using alens transducers 150 to be flat, which may minimize manufacturing costs. Both thelens 302 with theconcave surface 304 and thelens 310 with theconvex surface 310 may be configured to produce a fixed focus. - It may be possible to produce a lens that can adjust its shape to create different focuses. It may be possible to create an elastic, fluid-filled pocket that functions as a lens. The fluid can be pumped in or out of the lens to adjust shape of the pocket and thus the focus of the transducers.
-
FIG. 6 is a schematic view of atransducer 150 withmultiple elements 150 a-150 h that can be individually energized to produce a variety of acoustic waves, according to at least one aspect of the present disclosure. As shown inFIG. 6 ,multiple transducer elements 150 a-150 h can be arranged in an array to produce converging, diverging, or planar, acoustic waves. For examples, thetransducer elements 150 a-150 h can be activated in a predetermined sequence to selectively generate convergent/divergent/planar acoustic waves, such as, for example, the convergentacoustic wave 314, shown inFIG. 4 , or a divergentacoustic wave 312 shown inFIG. 5 . To generate a convergingacoustic wave 314, for example, theouter transducer elements inner transducer elements inner transducer elements inner transducer elements acoustic wave 314. The first, second, and third time delays may be equal or may vary in order to generate more complex acoustic waves. Alternatively, thetransducer elements 150 a-150 h may be energized in reverse order to produce a diverging acoustic wave using equal or different time delays. Thetransducer elements 150 a-150 h can be interchangeably configured to transmit or receive acoustic waves. -
FIG. 7 is a bottom view of atransducer 400 having aninternal element 420 surrounded byconcentric rings 410, according to at least one aspect of the present disclosure. Eachtransducer 150 can be adapted and configured to produce an acoustic wave with variable focus. One way to accomplish this can be with eachtransducer 400 having concentric rings 410 (e.g., an annular array) as shown inFIG. 7 . Eachconcentric ring 410 can be driven with a different signal. To focus the acoustic wave, the signal going to theinner element 420 may be progressively more delayed than the outer of theconcentric ring 410. The acoustic waves from eachconcentric ring 410 may converge at a point. To defocus the acoustic wave coming from an annular array, the acoustic wave at the outer of theconcentric rings 410 may be progressively more delayed relative to theinner element 420. One way to make an annular array can be withconcentric rings 410 of equal area. In another aspect, the annular array may compriseconcentric rings 410 of unequal area. -
FIG. 8 is a bottom view of a transducer comprisinginternal elements 452 arranged in 2-dimensional (2D)grid array 450, according to at least one aspect of the present disclosure. Eachinternal element 452 of the 2Dgrid transducer array 450 can be driven with a different signal. To produce a converging acoustic wave (e.g., “focus”), the signal applied to theinner element 454 may be progressively more delayed than the signal applied to the outer elements of the 2Dgrid transducer array 450. To produce a diverging acoustic wave (e.g., “defocus”), the acoustic wave produced by theouter elements 452 may be progressively more delayed relative to theinner element 454. In one aspect, each of theinternal elements 452 of the 2Dgrid transducer array 450 may define an equal area. In another aspect, each of theinternal elements 452 of the2D grid transducer 450 array may define an unequal area. - In one aspect, the
transducer transducer transducer FIG. 7 or as a grid array as shown inFIG. 8 . In another aspect, thetransducer - In one aspect, each of the
transducers FIGS. 4-8 , or elements thereof, are non-invasive and may be implemented in a suitable size and shape to fit on the body part of the patient. Also, the individual number and arrangement of transducer elements may be selected to fit on the body part of the patient. In one aspect, thetransducer transducer transducers transducers transducers 150 400, 450, or elements thereof, may be selectively energized and actuated to produce convergent, divergent, or planar acoustic waves as discussed in more detail in the following description. - With reference now to
FIGS. 4-8 , in one aspect, the acoustic wave produced by thetransducer transducer annular array 400 or a grid array 450). - In one aspect, the acoustic wave produced by the
transducer - In one aspect, the
transducers transducers transducers - In various aspects, the
transducers transducers transducers -
FIG. 9 is a diagram 470 of two acousticultrasonic pulses transducers FIG. 9 shows twopulses pulses pulse 474. If theacoustic pulse 472 on the left is delayed relative to theacoustic pulse 474 on the right, the twopulses acoustic pulse 474 on the right is delayed relative to theacoustic pulse 474 on the right, the twopulses - In another aspect, a mixture of convergent/divergent/planar acoustic waves may be timed to meet and constructively interfere at one location. A divergent acoustic wave may be timed to meet and destructively interfere at one location.
- Control of the converging and diverging wavefronts produced by the
transducers transducers - “Defocused” acoustic waves may be measured based on the volume of tissue treated according to the number of nodes and antinodes. A histogram of intensities or pressures over some volume may be employed to measure “defocused” acoustic waves. In one aspect, a dose-volume histogram may be employed in planning sonodynamic therapy. Alternatively, a cumulative histogram may be employed.
-
FIG. 10 is a diagram of anacoustic pulse packet 480 made of a repeating signal modulated by a Gaussian pulse signal, according to at least one aspect of the present disclosure. In one aspect, the acoustic wave generated by thetransducer acoustic pulse packet 480 may be produced by modulating a repeating signal, such as a sine wave, with a Gaussian pulse where the repeating signal is independent from the Gaussian pulse. When thetransducer -
FIG. 11 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of theskull 510 and brain of the patient andmultiple transducers 150 with onetransducer emitting energy 200 into the brain of the patient, according to at least one aspect of the present disclosure. It can be possible to take measurements or get a rough image of theskull 510 as shown inFIG. 11 . This can be facilitated if thetransducers 150 are fixed to a rigid shell and their relative positions and orientations are known. Rough measurements can be used to adjust the treatment algorithm by measured parameters such as skull thickness, “t.” Eachtransducer 150 may send out an acoustic pulse and listen for an echo. The echoes can be used for a quick estimate of the skull thickness, “t,” under eachtransducer 150. For treatment of tumors in other body parts of the patient, the sonodynamic therapy device may be adapted and configured to the couple to the body of the patient. - For designs with
transducers 150 that have an adjustable focus, the focus of eachtransducer 150 can be set beforehand with treatment planning. Alternatively, thetransducers 150 can adjust their focus automatically based on temperature readings of the head or based on skull thickness, “t,” measurements. - The amplitude of the electrical drive signal driving the
transducers 150 can be controlled or modulated. In some cases, it can be beneficial to modulate the electrical drive signal driving thetransducers 150 based on the temperature of the head or other body part being treated. For example, if the temperature sensors are detecting a sharp rise in temperature, the amplitude of thetransducers 150 can be decreased, shut off for a period, or the duty cycle can be decreased. By modulating the intensity of the acoustic pulses, the temporal average acoustic intensity may be regulated to activate the sensitizer while maintaining the temperature of the tumor cells below a temperature (e.g., below 42° C.) capable of causing thermal damage to the cell and in some circumstances necrotic cell death. In another aspect, sonodynamic therapy can function at a variety of different frequencies. Each frequency can transmit through askull 510 efficiently with certain thicknesses of skulls. Using a variety of frequencies can allow a non-invasivesonodynamic therapy device 100 to operate on a broad range of skull thicknesses, “t.” - In aspects where the
transducers 150 can operate at multiple frequencies, the frequency of eachtransducer 150 can be selected manually or automatically. As stated in the foregoing description, thetransducers 150 may be driven at ultrasonic frequencies in a range of about 20.00 kHz to about 12.00 MHz. More particularly, thetransducers 150 may be driven at ultrasonic frequencies in a range of about 650.00 kHz to about 2.00 MHz. In a preferred range, thetransducers 150 may be driven at ultrasonic frequencies in a range of about 900.00 kHz to about 1.20 MHz and more preferably at about 1.06 MHz. The frequencies can be preselected by a physician. The frequencies can be selected based on a measurement of head anatomy (e.g. skull thickness, “t”). For example, eachtransducer 150 can send out a sequence of pulses to measure the thickness of theskull 510 closest to it. Based on the result of the skull thickness, “t,” measurement, an algorithm can be used to select frequencies from a set of frequencies or from a range of frequencies that may be best suited for the skull thickness, “t,” and energize thetransducers 150 accordingly. - The size and shape of the
transducers 150, as can be seen inFIG. 2 , may vary across various disclosed aspects. For a cost-effective and simple system,larger transducers 150, which may have directional acoustic waves, may be used.Large transducers 150 can be made less directional by applying to eachtransducer 150 an acoustic lens that bends the acoustic waves as described further elsewhere herein. For a system that can conform to the skull,smaller transducers 150, which can radiate more broadly thanlarger transducers 150, can be used. Suchsmall transducers 150 can have a greater ability to image or beam steer as an array. - Instead of focusing an
acoustic wave 200 to a small point, theacoustic wave 200 can be defocused to minimize the spatial variation of the acoustic wave intensity in the brain as shown inFIG. 4 . The size and shape of thetransducers 150 may defocus or focus eachtransducer 150. Defocused transducers can be formed using atransducer 150 with a convex emittingsurface 310 as seen inFIG. 5 . As seen inFIG. 4 , design of the transducers can focus the sound from eachtransducer 150 using a concave emittingsurface 304 with a center of curvature where the sound can focus. As shown inFIG. 6 , an array oftransducers 150 a-150 h can be used to generate acoustic waves that are convergent, divergent, or more complex. - Each
transducer 150 can cycle through several frequencies so that at least one of the frequencies can transmit nearly optimally for the given skull thickness, “t.” Eachtransducer 150 may also sweep continuously from one frequency to another. A frequency can be pre-selected for eachtransducer 150 based on the thickness ofskull 510 nearest to it (e.g., during treatment planning by the physician). Prior to treatment, eachtransducer 150 can transmit test signals and monitor the reflected sound to automatically determine which frequency or frequencies can work best for that one of thetransducers 150. The test signals can be used to measure the skull thickness, “t,” directly by measuring delays in pulse echoes, or they can be used to detect the relative amount of reflected acoustic energy. - Each
transducer 150 can be made up of a broad-spectrum ultrasonic transducer or can be made up of several smaller transducers (e.g., piezo-electric elements as shown inFIGS. 6-8 ) designed to work at particular frequencies. Eachtransducer 150 can have an element specifically designed to monitor the waves reflected from the head. In the case where thetransducers 150 are made of severalsmaller transducers 150, while onetransducer 150 is transmitting sound, theother transducers 150 may be used to monitor the incoming acoustic pulses. - Of all the frequencies that work with sonodynamic therapy, a subset of frequencies can be selected to best cover a range of common skull thicknesses, “t.” Frequencies that share many common factors (e.g., harmonics such a 1 MHz and 2 MHz) may not make good choices to cover the most number of skull thicknesses because many of the transmission peaks between the two frequencies can be shared. Frequencies without many or any common factors (e.g., coprime numbers) may make for good choices for frequencies because the transmission peaks can occur at different skull thicknesses.
-
FIG. 12 is achart 700 showing an intensity transmission ratio across multiple frequencies, according to at least one aspect of the present disclosure. As shown inFIG. 12 , the transmission of 5 different frequencies across different skull thicknesses between 4 mm and 9 mm. Afirst frequency 702 at 1.107 MHz, asecond frequency 704 at 1.052 MHz, athird frequency 706 at 1.000 MHz, afourth frequency 708 at 0.961 MHz, and a fifth frequency at 0.898 MHz. There can be good coverage of different skull thicknesses. In this example, each skull thickness can have at least one frequency that can transmit 75% or more of its energy. This can be accomplished with frequencies between 898 kHz and 1.107 MHz, a range of only 0.2 MHz - Transmission of sound through an absorbing layer of tissue may not monotonically decrease as function of thickness. Instead, transmission can be enhanced when the thickness of the skull is a multiple of half the wavelength of the sound in that layer. Similarly, when the thickness of the skull is an odd multiple of quarter wavelengths (halfway between A/2 multiples), the transmission can be reduced.
-
FIG. 13A is achart 720 showing an intensity transmission and pressure reflection ratio at 1 MHz versus skull thickness in millimeters andFIG. 13B is achart 730 showing a transmission and reflection ratio at 1 MHz versus skull thickness in wavelengths, according to at least one aspect of the present disclosure. As shown inFIGS. 13A and 13B , the transmission of a 1 MHz soundwave through various skull thicknesses.FIG. 7A shows the skull thickness in millimeters andFIG. 13B shows the skull thickness in multiples of wavelength of theintensity transmission ratio 722 and thereflection ratio 724. Theintensity transmission ratio 722 can reach a peak whenever the skull is a multiple of a half wavelength. Likewise, the ratio of sound reflected shown as thereflection ration 724 can be at a minimum whenever the skull is a multiple of a half wavelength. - The
intensity transmission ratio 722 and thepressure reflection ratio 724 can be functions of both the skull thickness and the frequency.FIG. 14A is achart 740 showing anintensity transmission ratio 722 as a function of frequency andFIG. 14B is achart 750 showing areflection ratio 724 as a function of frequency, according to at least one aspect of the present disclosure. To the right of thechart 740 inFIG. 14A is ascale 742 of theintensity transmission ratio 722 ranging from 0.0 to 1.0 and the right of thechart 750 inFIG. 14B is a scale of thereflection ratio 724 ranging from −1.0 to +1.0.FIGS. 14A and 14B show how theintensity transmission ratio 722 and thereflection ratio 724 change with skull thickness and frequency. Negative reflection ratios can be achieved wherever peak transmission may be occurring. Negative reflection ratios can indicate that the reflected wave can be phase shifted 180° relative to the incident wave. As shown in thechart 740 ofFIG. 14A , theintensity transmission ratio 722 has amaximum ratio 744 of about 1.0 and aminimum ratio 746 of about 0.4, which is consistent with the maximum/minimum ratios shown incharts FIGS. 13A and 13B . Thechart 750 shown inFIG. 14B shows that thereflection ratio 724 has aminimum ratio 754 of about 0.0 and amaximum ratio 756 of about 0.8, which is consistent with maximum/minimum ratios shown in thecharts FIGS. 13A and 13B . - Frequencies that are different by an irrational number may make good choices because they can have peak transmissions at different thicknesses. The golden ratio (e.g., the “most irrational number”) may be useful in selecting frequencies. It may not be sufficient for selected frequencies' transmission to avoid peaking at the same skull thickness, “t.”
- It can also be allowable for two frequencies to share a peak transmission at a certain thickness, provided that the shared peak occurs at a skull thickness, “t,” outside of the thicknesses expected to occur naturally. If the device can select the best frequency (e.g., the greatest transmission ratio) at each skull thickness, “t,” then to get optimal coverage across many skull thicknesses, “t,” with a limited number of frequencies can mean to maximize the average transmission ratio of the best frequency across the selected skull thicknesses, “t,” or to maximize the minimum transmission ratio of the best frequency within the selected skull thicknesses, “t.”
- Hair on the patient's head may need to be shaved or shortened to allow for efficient transmission of sound into the brain. Some aspects may allow the hair to remain untouched. A comb-like structure can be able to pass through hair to contact the skull in many locations to transmit sound. The hair may also be wet and matted down to allow for the sound to transmit relatively unimpeded.
-
FIG. 15 is achart 760 showing the field strength of aplanar wave 762 into a multi-tissue skull model, according to at least one aspect of the present disclosure. With reference toFIG. 15 , the skull may absorb a large proportion of the ultrasonic energy in a short distance. The insertion loss 764 (the amount of energy that can be lost by adding the skull into the acoustic wave 200) can be centered around 12 dB. Every additional 3 dB worth of loss can correspond to approximately half of the energy being reduced. A 12 dB loss can be equivalent to a sixteenth of the energy introduced at the surface of the skin being left at the surface of the skull. Because of this, the skull may heat up during transcranial sonodynamic therapy. - Table 1 is a summary of the parameters that can be used in the model of the skull. In addition to the intrinsic acoustic properties of the skull, the skin can be assumed to be 2.5 mm thick, and the skull can be assumed to be around 6.8 mm thick.
FIG. 15 shows the acoustic intensity in terms of field strength (dB) as a function of distance within the head model. Theinsertion loss 764 highlighted region emphasizes the jumps of energy lost at the interfaces and steep attenuation within the skull. -
TABLE 1 Parameters Used In The Model Of The Skull Interface Transmission Loss Interface Ratio dB Skin-Bone T = 0.650 −1.87 Bone-Skin T - 0.567 −2.46 Frequency 1 MHz Attenuation Skin −0.5 dB/(cm-MHz) Bone −11.1 dB/(cm-MHz) Brain −1 dB/(cm-MHz) Acoustic Impedance Skin 1.99 Kg/sec-m2) × 106 Bone 7.75 Kg/sec-m2) × 106 Brain 1.6 Kg/sec-m2) × 106 - The model uses an average of various human skull thicknesses. The thickness of the “frontal, parietal and occipital bones were (in mm) 6.58, 5.37 and 7.56, respectively, for the male; and 7.48, 5.58 and 8.17, respectively, for the female.” As mentioned elsewhere herein, human skulls vary considerably by gender and anatomical location. The model can represent an average amount of attenuation, but thicker sections of skull can have a greater amount of attenuation. In general, every additional 2.7 mm worth of skull can increase the attenuation by 3 dB (a factor of 2).
- This model can be based on a simple plane wave model impinging on planar layers of tissue. Each layer of tissue can be assumed to be homogenous and uniform thickness. The effect of the acoustic wavelength (λ) matching with various thicknesses of skull are ignored in this model. It can also be assumed that all reflected waves are lost and do not reenter the brain.
- Pichardo et al. investigated the transmission of ultrasound through freshly excised human skulls at various frequencies. They report the ratio of absorbed energy for seven skulls at several locations at the frequencies of 0.270, 0.836, and 1.402 MHz. While they did not measure the energy lost at 1 MHz specifically, their study allows interpolation and estimation that the insertion loss can be centered around 12 dB. Their study also can confirm that the insertion loss can be expected to vary by skull and anatomical location.
-
FIG. 16 is achart 770 showing the energy absorbedratio 772 of a freshly excised human skull at multiple frequencies, according to at least one aspect of the present disclosure. As shown inFIG. 16 , Pinton et al. also measured the attenuation at 1 MHz of nine points along an 8 mm thick section of skull bone and found an insertion loss of 12.6±1.33 dB (higher loss due to a thick skull section). Both the simplified head model and measurements taken from different laboratories agree that the insertion loss (the amount of energy lost by adding the skull into the model) can be centered around 12 dB (a factor of 16) with considerable variation. - The energy lost as the sound passes through the skull may be converted into heat primarily in the skull. The temperature of the skull can begin to heat up and, over time, heat can disperse to nearby tissue. Most of the heating can originate at the outer surface of the skull and disperse into the skin and other layers of bone. Above certain intensities, the blood can be unable to transport enough heat away, and the temperature in the bone and skin can rise to unsafe levels. Adding more transducers into the system can decrease the intensity at which this threshold can be reached because the blood can be warmed by each successive transducer it passes and lose its ability to absorb additional heat from the tissue.
- There can be several ways to combat the effects of heating. In particular, cooling, intermittent treatment, monitoring, and transducer modulation can be used to reduce the consequences of heating.
-
FIG. 17 is a partial cutaway view of a transcranial sonodynamic therapy device placed over the head of a patient showing a partial view of themultiple transducers 150 and a full view of acooling system 600, according to at least one aspect of the present disclosure. Thecooling system 600 shown inFIG. 17 may be implemented to keep the temperature of the skull and surrounding tissue within safe levels. A cooling layer (e.g., of water) may be provided between thetransducers 150 and the patient's head. The cooling layer can be made of a flexible membrane or balloon that can conform to each patient's head. A large cooling layer may be reusable and, thus, may require cleaning between each use. - The
cooling system 600 can be made of a flexible cavity (not shown) with an inlet and an outlet for a coolant such as water to circulate. The head of the patient can be inserted into a concave shape (e.g., a “bowl”) with an elastic opening. The elastic opening can seal against the head of the patient. Water can fill up the space between the patient's head and the bowl. - Similar to the single cavity design, water can be circulated to keep the temperature of the water from rising. One advantage of such a system can be that water in the
cooling system 600 can be in direct contact with the patient's head. The air around the patient's hair can be removed by the water, which may help couple theultrasound transducers 150 to the patient's head. -
FIG. 18 is perspective view of apatient interface 650, according to at least one aspect of the present disclosure. Thecooling system 600 can be acap 160 with coolingchannels 630 distributed throughout. Thecap 160 can have one long loop of coolingchannels 630, or it can have several independent loops. A system with several cooling loops can be connected to a single inlet and outlet tube via a manifold, or they can be controlled independently. Water or other heat transfer fluid can be circulated through the coolingchannels 630 to exchange heat generated either by thetransducers 150, the patient's body, or a combination thereof. - Water can flow past all regions of the head that can absorb heat. The water can be pumped to keep the water temperature from rising which would decrease the cooling efficacy of the water. Like patches with
multiple transducers 150, each patch may have itsown cooling channels 630. The coolingchannels 630 can be water-filled tubes that may be larger and heavier than the wires going to thetransducers 150. The number ofunique cooling channels 630 can be optimized to avoid excessive weight in the cooling layer. - The effect of heating can be readily monitored with temperature sensors and reduced with the
fluid cooling system 600. A layer of cool, degassed water between theultrasonic transducers 150 and the head can serve a dual function of coupling the head to thetransducers 150 and controlling the temperature of the skull. Prior to any insonication, the head can be cooled for several minutes by a constant flow of cool water. Once the treatment begins, the temperature of the skull can be monitored continuously, which can modulate the treatment over the entire skull, or it can individually modulate eachtransducer 150. Even without continuous monitoring of the skull temperature, a safe treatment algorithm can be devised with intermittent treatment and continuous cooling with a margin of safety for all patients. Intermittent treatment can also be more effective than the same effective treatment time done continuously due to the rate limiting step of oxygen diffusion around the sonosensitizer. - It can be likely that just surface temperature monitoring can be necessary. In any case, it can be possible to monitor the temperature throughout the skull using a variety of thermometry of deep-seated tissues. Any surface measurements of temperature may need to be insulated from the cooling layer of water to prevent the probe from being dominated by the cooling layer's effect.
- The temperature of the patient's head may need to monitored. If temperature sensors (not shown) are simply placed between the cooling layer and the head, the temperature sensor can be reading some combination of the head temperature and the cooling layer temperature.
- There can be several ways that the temperature sensor can be isolated from the temperature of the cooling layer. A layer of insulation can be placed between the cooling layer and each temperature sensor. In such instances, the area around each temperature sensor can receive less or no cooling.
-
FIG. 19 is achart 800 showing therelative sensitivity plot 802 of an infrared (IR) temperature sensor, according to at least one aspect of the present disclosure. As shown inFIG. 19 , a temperature probe (not shown) that measures only in one direction (e.g., unidirectional) can be utilized. An example of a unidirectional temperature sensor can be an IR temperature sensor. IR temperature sensors measure the infrared light being emitted by an object via black body radiation. IR temperature sensors accept radiation coming in from a small range of angles (e.g., an acceptance cone). In this application, one or more IR sensors can be oriented so that the cone of acceptance of each sensor can be facing the patient's head. One or more methods above can be combined to accurately monitor the temperature of the patient's head. -
FIG. 20 is a block diagram of a general non-invasivesonodynamic therapy system 900, according to at least one aspect of the present disclosure. The non-invasivesonodynamic therapy system 900 comprises acontroller 902 coupled to anultrasonic transducer array 904 to control the operation of theultrasonic transducer array 904 to generate a suitable ultrasonic acoustic wave. Theultrasonic transducer array 904 is coupled to apatient interface 906 to couple the ultrasonic acoustic wave produced by theultrasonic transducer array 904 to asensitizer 908 that accumulates in tumor cells within the patient's body. Through a process called sonoluminescence, the ultrasonic acoustic wave produces light that activates thesensitizer 908 and causes necrosis of the tumor cells. - Sonodynamic therapy treatment employs a
sensitizer 908 drug that only become cytotoxic upon exposure to ultrasound. Upon activation, sonodynamic therapy drugs generally referred to as “sonosensitisers” produce ROS that generate the cytotoxic effect to kill the tumor cell. Sonodynamic therapy provides much greater tissue depth that can be reached non-invasively by ultrasound as compared to in over photodynamic therapy. In one aspect, thesensitizer 908 may comprise 5-aminolevulinic acid (5-ALA) amongother sensitizers 908 such as hematoporphyrin, Rose Bengal, curcumin, titanium nanoparticles, chlorine e6, and any combinations thereof. In addition, the sonodynamic process may comprise injecting microbubbles into the tumor tissue to “seed” cavitation, enabling bubble to accumulate in the tumor tissue, or injecting a drug to oxygenate tumor tissue. The sonodynamic therapy process described herein may be combined with one or more other adjuvant therapies such as chemotherapy, immunotherapy, radiotherapy, and/or HIFU. - The non-invasive
sonodynamic therapy system 900 may be employed to treat a variety of tumors and to treat the area around the tumor cavity, whether malignant or nonmalignant. The area around the tumor cavity includes cells that cause the recurrence and eventual mortality in malignant tumors. In one aspect, the non-invasivesonodynamic therapy system 900 may be configured to treat prostate cancer via trans-rectal ultrasound sonodynamic therapy and cervical cancer via trans-vaginal ultrasound sonodynamic therapy, for example. - In one aspect, the
controller 902 may be configured to drive theultrasonic transducer array 904. Thecontroller 902 may be configured to execute one or more than one control algorithm setup/reflection assessment and tune the drive frequency to skull thickness. This can be done automatically. In one aspect, the control algorithm may be configured to pulse or control the “duty cycle” of theultrasonic transducer array 904 drive waveform to generate high temporal peak acoustic intensity of ultrasonic acoustic waves with low temporal average acoustic intensity sufficient to activate thesensitizer 908 while preventing thermal necrotic death of the tumor cells in the treatment region. In another aspect, the control algorithm may be configured to generate packets of waves that are delayed to overlap the tumor. In another aspect, the control algorithm may be configured to control the intensity of the ultrasonic acoustic wave. - In another aspect, the control algorithm may be configured to control the phase of the ultrasonic acoustic wave. In another aspect, the control algorithm may be configured to randomize the phase of the ultrasonic acoustic wave. Modulating acoustic waves with phase randomization promotes broad consistent coverage across a treatment region where acoustic wavefronts constructively combine at varying pseudo random locations within the treatment region, rather than the exact same location with each cycle. This control scheme provides a more homogeneous treatment region to aid broad consistent treatment coverage and avoid sub therapeutic dead spots in the treatment region. Phase randomization provides additional benefit in adapting to the treatment environment. Repeating the exact same excitation pattern in some types of acoustical environments could lead to the potential for standing waves to form. Standing waves are inherently dangerous as they can deliver unintended treatment energy to the patient. A controller scheme that provides phase randomization of the acoustic waveform can mitigate the risks of repetitive excitation that can lead to standing waves.
- A feedback loop may be provided back to the
controller 902 to adjust the drive signal to theultrasonic transducer array 904 based on in situ variables such as tissue depth, tissue thickness, tissue volume, skull thickness, temperature, among other variables. In one aspect, thecontroller 902 may be located in an ultrasonic generator or may be located elsewhere. In various aspects, in situ variables may include a disease state or an inner body location. The disease state may include alternative treatment ultrasonic transducer probe that is driven differently for each disease state. Examples of feedback loops are described hereinbelow in connection withFIGS. 22-24 . - In one aspect, the
ultrasonic transducer array 904 may be configured according to thetransducers ultrasonic transducer array 904 may be configured to couple ultrasonic acoustic waves in various locations on the patient's body other than the head. For example, theultrasonic transducer array 904 may be configured to generate ultrasound that activates asensitizer 908 to treat tumors in the brain, such as glioblastoma, lung, breast, stomach, liver, pancreas, intestines, rectum, colon, vagina, testes, among others, whether the tumors are malignant or nonmalignant. - In various configurations, the
ultrasonic transducer array 904 is non-invasive and produces ultrasonic acoustic waves capable of reaching the target tumor cells non-invasively. As described hereinabove, theultrasonic transducer array 904 may be configured as annular array, 2D grid array, a linear array, and the like, to generate an adaptively focused ultrasonic acoustic wave optimized based on in situ variables such as tissue depth, tissue thickness, tissue volume, skull thickness, among other variables. In other aspects, theultrasonic transducer array 904 may adaptively focus or adjust the ultrasonic acoustic wave based on pretreatment planning or safety. In one aspect, thecontroller 902 executes a control algorithm to generate selectively convergent/divergent ultrasonic acoustic waves including adaptive focus for collaborative transducer performance. The ultrasonicacoustic array 904 may be configured to perform transmitter and receiver functions that may be controlled by thecontroller 902. - The
ultrasonic transducer array 904 is coupled to thepatient interface 906 to facilitate acoustic coupling of the ultrasonic vibrations generated by theultrasonic transducer array 904 into the patient's body. Thepatient interface 906, like theultrasonic transducer array 904, is non-invasive. In one aspect, thepatient interface 906 may be configured to remove air between theultrasonic transducer array 904 and the patient's body to facilitate acoustic coupling. In one aspect, thepatient interface 906 may be configured to remove excess heat from the patient's body. In some configurations, thepatient interface 906 may comprise a variety of sensors, such as a temperature sensor, for example. Signals from such sensors may be provided as feedback to the controller 902 (seeFIG. 22 for example). Such feedback may be employed to control theultrasonic transducer array 904 to generate a desired ultrasonic acoustic wave. Thepatient interface 906 also may include gel or hydrogel layers to improve the acoustical coupling between theultrasonic transducer array 904 and the patient's body. In one aspect, the patient interface 1022 may be configured to locally apply cooling. In one aspect, the patient interface 1022 may be configured for sensor feedback to theprocessing unit 902. - Finally, the non-invasive
sonodynamic therapy system 900 comprises asensitizer 908 that may be absorbed by the tumor cells. Sonodynamic therapy requires the combination of thesensitizer 908, such as a sensitizing drug, ultrasound generated by theultrasonic transducer array 904 coupled into the patient's body by thepatient interface 906, and molecular oxygen. Although these components are non-toxic individually, when combined together, a cytotoxic ROS is generated to kill the tumor cells. Sonodynamic therapy may be configured to provide penetration of ultrasound through the patient's body and can be used to treat a wide array of deep and hard to access tumors. -
FIG. 21 is an illustrative diagram 1000 of thesonodynamic therapy system 900 shown inFIG. 20 , according to at least one aspect of the present disclosure. In one aspect, thesonodynamic therapy system 900 comprises acontroller 902 that may be located in anultrasonic generator 1002. Theultrasonic generator 1002 comprises acontroller 1012, auser interface 1004, afoot switch 1006 for activating thecontroller 1012, and a cap orhelmet 1008 that is placed over the head of the patient. Acable 1010 that carries electrical signals to and from theultrasonic transducer array 904 couples thetransducer array 904 and theultrasonic generator 1002. Theultrasonic transducer array 904 comprises an array ofultrasonic transducers patient interface 906 such as theskull cap 160. Theultrasonic generator 1002 drives theultrasonic transducers acoustic wave 200 that is coupled into the body of the patient to excite thesensitizer 908 ingested by the patient and absorbed by the tumor cells. Thecontroller 1012 shapes the acoustic wave to achieve a convergent, divergent, or planar acoustic wave, or more complex acoustic waves. As previously described, in one aspect thesensitizer 908 may comprise and ALA sensitizing drug that is activated in a sonoluminescence process, for example. -
FIG. 22 is a schematic diagram 1100 of thesonodynamic therapy system 900 shown inFIGS. 20 and 21 , according to at least one aspect of the present disclosure. Thecontroller 902 of thesonodynamic therapy system 900 comprises auser interface 1102 coupled to aprocessing unit 1104 and configured to receive input from a user and providing output to the user. Theprocessing unit 1104 may be a processor or microcontroller coupled to a memory, a control circuit, or a combination thereof. Theultrasonic transducer array 904 comprises one or more than oneultrasonic transducer 1114 and one or more than one monitoringultrasonic transducer 1116. It will be appreciated that the same ultrasonic transducer element may be configured to implement an ultrasonic transmitter function as well as a receiver function (seeFIG. 24 for example). Thepatient interface 906 comprises one or more than onetemperature sensors 1118 to monitor the temperature of thepatient 1122. Thepatient interface 906 also comprises acooling system 1120 to reduce the temperature of thepatient 1122. In one aspect, thepatient interface 906 may be configured to eliminate air gaps between thetransducer 1114 and thepatient 1122 to enable acoustical coupling. - The
processing unit 1104 is configured to execute machine executable instructions to implement various control algorithms as previously described. Theprocessing unit 1104 may comprise a memory to store such machine executable instructions and processing engines to execute the control algorithms. Theprocessing unit 1104 also may be implemented in hardware with digital and analog electronic components. Theprocessing unit 1104 is coupled to amultiplexing system 1112 and apower source 1106 suitable for driving theultrasonic transducers 1114. - The
ultrasonic transducers 1114 are coupled to the body of thepatient 1122 to activate thesensitizer 908 administered to thepatient 1122. In one aspect, at least one sonosensitizer 908 agent may be configured for preferential accumulation in selective tissue of thepatient 1122. Monitoringultrasonic transducers 1116 monitor acoustic feedback from thepatient 1122 and generate signals that are provided as feedback to theprocessing unit 1104 via an analog-to-digital converter 1110 (ADC). In addition to the acoustic feedback, apower monitoring device 1108 monitors thepower source 1106 and provides feedback to theprocessing unit 1104 through theADC 1110. Theprocessing unit 1104 controls the ultrasonic transducer drive signals based on the acoustic feedback signal and/or the power monitoring signal to achieve a desired ultrasonic acoustic wave inside the body of thepatient 1122. In one aspect, at least oneultrasonic transducer 1114 is configured to output selectively convergent and divergent acoustic waves. Thetransducer 1114 may be configured in an annular array or a grid array. Thetransducer 1114 may be configured with multiple electrodes. Thetransducer 1114 may be configured to receive reflected acoustical signals. - The
processing unit 1104 is coupled to thetemperature sensors 1118 and receives patient temperature feedback through theADC 1010. Theprocessing unit 1104 controls thecooling system 1120 based at least in part on the patient temperature feedback signal. - In one aspect, the
processing unit 1102 is configured to produce a pulsed acoustical signal with temporal-average intensity output below 8 W/cm2. Theprocessing unit 1102 is adapted to apply amplitude-modulated acoustical signals including constructive interference over a plurality of wave cycles. Theprocessing unit 1102 further may be configured to output packets of acoustic waves at various delayed sequences to provide diffused tissue coverage. Theprocessing unit 1102 may be configured to execute frequency adaptive algorithms to optimize transmission of acoustical signals. Theprocessing unit 1102 may be configured to control phased randomization of acoustical signals. - In various aspects, the present disclosure provides a sonodynamic therapy device comprising a
transducer 904, apatient interface 906, and acontroller 902 adapted to activate asensitizer 908 within the body of thepatient 1122. Thetransducer 904 may comprise one or more than onetransducer controller 902 is configured to generate a broadband range of ultrasonic frequencies to drive thetransducer 904 and produce divergent, convergent, or planar acoustic waves. - In one aspect, the
patient interface 906 is configured to transmit acoustic waves produced by the transducer(s) 904 into the body of thepatient 1122 thus acoustically coupling the transducer(s) 904 to thepatient 1122. In one aspect, thepatient interface 906 provides acooling system 1120 to remove any excess heat that builds up in thepatient 1122 as a of the coupling acoustic energy to the body of thepatient 1122. In one aspect, thepatient interface 906 may comprise anintegral cooling system 1120. Thepatient interface 906 may comprise a hydrogel cap filled with gel or a water-filled cap with cooling channels. In one aspect, thepatient interface 906 comprises one or more than onesensor 1118 to provide feedback to theprocessing unit 1104 of thecontroller 902. Thesensors 1118 my include, for example, temperature sensors, optical temperature sensors to measure temperature in a particular direction, acoustic sensors, which may include thesame transducers 904 used for transmitting acoustic signals. Thepatient interface 906 may be configured to remove air from thepatient interface 906 to improve acoustic coupling between thetransducer 904 and the body of thepatient 1122. In anther aspect, thepatient interface 906 may be configured to cool thepatient 1122. In yet another aspect, thepatient interface 906 may be configured to cool thetransducers 904, for example, to keep the transducers at the same temperature to achieve frequency stability. - In one aspect, the
patient interface 906 may be adapted and configured to fit various patient anatomies. For example, thepatient interface 906 may be adapted and configured to fit patient anatomies for sonodynamic therapy specifically adapted to treat tumors located in the brain, lung, breast, stomach, liver, pancreas, intestines, rectum, colon, vagina, testes, among others, for example. A sonodynamic therapy device may be adapted to wrap around the torso or limb of the patient and/or employed to treat osteosarcoma into the bone. Thecontroller 902 may be adapted to detect either thepatient interface 906 or the sonodynamic therapy device such as thetransducer 904 orpatient interface 906 and select a treatment algorithm to produce acoustic waves optimized for treating the various tumors. Thetransducer 904 orpatient interface 906 may be identified using identification (ID)circuits ID circuit transducer 904 orpatient interface 906 and associating the impedance with a treatment algorithm. - In one aspect, the
controller 902 is configured to generate electrical drive signals to actuate one or more than oneultrasonic transducer 904 to produce an acoustic wave to activate asensitizer 908 located within the body of thepatient 1122. In one aspect, the electrical drive signals generated by thecontroller 902 may actuate the one or more than oneultrasonic transducer 904 to produce acoustic waves of varying intensities, amplitudes, or frequencies. In another aspect, the acoustic waves may be amplitude modulated, frequency modulated, phase modulated, continuous, discontinuous, pulsed, randomized, or combinations thereof. In other aspects, the acoustic waves my be produced in a packet of wave cycles, where the number of cycles per packet may be predetermined to achieve a desired outcome that is different from a focused ultrasound pulse, for example. In other aspects, thecontroller 902 is configured to generate a frequency modulation signal to produce a frequency-modulated acoustic wave. In one aspect, the controller may be configured to generate an intra or inter pulse variation signal that can be used to reduce standing acoustic waves. - In one aspect, the
controller 902 is configured to apply an amplitude-modulated acoustic ultrasound signal which constructively interferes over a plurality of wave cycles. In one aspect, the intensity of each of the plurality of acoustic waves remain within a safe range wherein the ultrasound energy carried by each of the plurality of acoustic waves is safe to the tissue of thepatient 1122, such as the brain or other body part. In one aspect, thecontroller 902 may be configured to drive thetransducer 904 to generate an amplitude-modulated acoustic wave which produces a constructive wavefront. - In one aspect where the sonodynamic therapy device comprises one
transducer 904 and thecontroller 902 may be configured to generate a drive signal to actuate thetransducer 904 to produce a long acoustic ultrasonic wave packet In one aspect, thecontroller 902 may be configured to generate a drive signal to actuate thetransducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a Gaussian pulse (seeFIG. 10 for example). In another aspect, thecontroller 902 may be configured to generate a drive signal to actuate thetransducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a rectangular pulse. In another aspect, thecontroller 902 may be configured to generate a drive signal to actuate thetransducer 904 to produce an ultrasonic acoustic wave packet composed of a sinusoidal wave amplitude modulated by a triangular pulse. The ultrasonic acoustic wave packet may comprise intra or inter wave packet variation. In one aspect, thecontroller 902 may be configured to generate a drive signal to actuate thetransducer 904 to produce an acoustic ultrasonic pulse. The acoustic wavefronts of the ultrasonic pulse may either converge to focus the ultrasonic energy to a specific region or diverge to spread the ultrasonic energy to a larger region. - In other aspects, where the sonodynamic therapy device comprises two or
more transducers 904 and thecontroller 902 may be configured to generate a drive signal to actuate the two ormore transducers 904 to produce acoustic ultrasonic pulses where the individual wavefronts, whether converging or diverging, will meet at the same location at the same time to focus the ultrasonic energy. In one aspect, thecontroller 902 may adapt the frequency drive for eachtransducer 904. -
FIG. 23 is a schematic diagram of asonodynamic therapy system 920 with aseparate transmitter transducer 930 andreceiver transducer 934, according to at least one aspect of the present disclosure. Thesonodynamic therapy system 920 comprises asystem controller 922 to control asignal generator 924 to generate an electrical signal to drive thetransmitter transducer 930. The electrical signal is amplified by anamplifier 926 and the drive signal is coupled to thetransmitter transducer 930 by amatching network 928 to maximize power transferred to thetransmitter transducer 930. Thetransmitter transducer 930 transmits an acoustic wave into tissue 932 (e.g., lesions) in the treatment region. Areceiver transducer 934 detects acoustic waves emitted by thetissue 932. The output of thereceiver transducer 934 is a weak electrical signal that is provided to anelectronic pre-amplifier 936 that converts the weak electrical signal into an output signal strong enough to be noise-tolerant and strong enough for further processing such as filtering by afilter 938. The output of thefilter 938 is provided to an analog-to-digital converter 940 (ADC) that provides a feedback signal to thesystem controller 922 in digital form. Based on the feedback signal received from thereceiver transducer 934 thesystem controller 922 can adjust the drive signal applied to thetransmitter transducer 930. The adjustment may include adjusting the modulation, strength, frequency, phase, or randomization, of the drive signal, or any combinations thereof. The feedback signal may represent tissue depth, tissue thickness, tissue volume, skull thickness, temperature, distance to the treatment region, or a combination thereof. -
FIG. 24 is a schematic diagram of asonodynamic therapy system 950 with a single transmitting and receivingtransducer 962, according to at least one aspect of the present disclosure. Thesonodynamic therapy system 950 comprises asystem controller 952 to control asignal generator 954 to generate an electrical signal to drive thetransducer 962 in transmitter mode. The electrical signal is amplified by anamplifier 956 and is applied to a transmitter/receiver (T/R)switch 958. When thetransducer 962 is in transmitter mode, the T/R switch 958 couples the drive signal to thetransducer 962 via amatching network 960 to optimize power transferred to thetransducer 962. In transmitter mode, thetransducer 962 transmits an acoustic wave into tissue 964 (e.g., lesions) in the treatment region. In receiver mode, thetransducer 962 detects acoustic waves emitted by thetissue 964. The output of thetransducer 962 is a weak electrical signal that is coupled to the T/R switch 958 by thematching network 960. The T/R switch 958 provides the weak electrical signal to anelectronic pre-amplifier 966 that converts the weak electrical signal into an output signal strong enough to be noise-tolerant and strong enough for further processing such as filtering by afilter 968. The output of thefilter 968 is provided to anADC 970 that provides a feedback signal to thesystem controller 952 in digital form. Based on the feedback signal received from thetransducer 962 in receiver mode, thesystem controller 952 can adjust the drive signal applied to thetransducer 962 in transmitter mode. The adjustment may include adjusting the modulation, strength, frequency, phase, or randomization, of the drive signal, or any combinations thereof. The feedback signal may represent tissue depth, tissue thickness, skull thickness, temperature, distance to the treatment region, or a combination thereof. - Having described various aspects of a
sonodynamic therapy system sonodynamic therapy system sonodynamic therapy systems FIGS. 25-31 hereinbelow will be described in connection withFIGS. 20-24 . -
FIG. 25 is an overview of asonodynamic therapy process 1200, according to at least one aspect of the present disclosure. In afirst phase 1202 of the sonodynamic therapy process, the patient is administered asonodynamic sensitizer 908 as described herein, and dons anultrasonic transducer array 904 comprising a plurality ofultrasonic transducers 150. Thesonodynamic sensitizer 908 may be administered orally or through other natural orifices, by injection, intravenously, topically, or other suitable technique. In asecond phase 1204 of the sonodynamic therapy process, thesonodynamic sensitizer 908 accumulates intumor cells 1206. In athird phase 1208 of thesonodynamic therapy process 1200, an ultrasoundacoustic wave 1210 generated by theultrasonic generator 1002 activates thesonodynamic sensitizer 908. In afourth phase 1212 of thesonodynamic therapy process 1200, thesonodynamic sensitizer 908 instigates a sequence of death of atumor cell 1206. -
FIG. 26 is a diagram 1300 of atumor cell 1206 illustrating the initial stage of selective accumulation of asensitizer 908, according to at least one aspect of the present disclosure. In the illustrated example, thesensitizer 908 is absorbed 1302 into themitochondria 1304 of thecancer cell 1206. The patient is administered 5-ALA,pro drug sensitizer 908, orally, which puts theheme 1306biosynthesis pathway 1316 into overdrive. In general, the body's natural feedback mechanism prevents the production of toomuch heme 1306.Heme 1306 will result in lower activity of the aminolevulinic acid synthase (ALAS) enzyme which produces 5-ALA endogenously. By introducing thesensitizer 908 exogenously,heme 1306 biosynthesis keeps producing even though the ALAS enzyme is inactivated. As a result, protoporphyrin IX 1308 (PpIX) accumulates preferentially in many types ofcancer cells 1206 including glioblastoma multiforme (GBM).PpIX 1308 is a catalyst that converts dissolved molecular oxygen into ROS by absorbing photons.Protoporphyrin IX 1308 is in the same class of molecules as chlorophyll (i.e., porphyrins), and is capable of converting light into chemical energy. -
FIG. 27 is a diagram 1320 of thecancer cell 1206 illustrating the increasedselective accumulation 1322 of thesensitizer 908, according to at least one aspect of the present disclosure. As shown inFIG. 27 , thePpIX 1308 is an active compound and the second to last intermediate product in theheme 1306biosynthesis pathway 1316. The accumulation ofPpIX 1308 in thecancer cell 1206mitochondria 1304 is due to increasedaccumulation 1322 of the 5-ALA sensitizer 908 and reduced conversion ofPpIX 1308 into heme 1306 (reduced expression of ferrochelatase). -
FIG. 28 is a diagram 1330 of thecancer cell 1206 shown inFIGS. 26 and 27 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure. Theultrasonic transducer 904 generates an ultrasoundacoustic wave 200 that penetrates thecancer cell 1206 and themitochondria 1304. The ultrasoundacoustic wave 200 produces light 1312 through a process called sonoluminescence. Sonoluminescence occurs when the ultrasoundacoustic wave 200 collapsesfluid bubbles 1332 causingcavitation 1334 and produces light 1312 in the process. The production of light 1312 happens far away from theultrasonic transducer 904. The light 1312 produced through sonoluminescence activates thePpIX 1308 to produceROS 1336. Sonoluminescence can occur anywhere the intensity of the ultrasoundacoustic wave 200 is sufficient, which allows sonodynamic therapy to treat much deeper than photodynamic therapy. TheROS 1336 species cause oxidative stress which results in thecancer cell 1206 undergoing programmed cell death 1314 (apoptosis), which is the same as photodynamic therapy. -
FIG. 29 is a diagram 1400 illustrating the sonoluminescence process, according to at least one aspect of the present disclosure. The diagram 1400 can be found in Detlef Lohse, Sonoluminescence, Inside a micro-reactor, Nature volume 418, pages 381-383 (2002), which is incorporated herein by reference. In a standing ultrasonicacoustic wave 200, at low sound-wave pressure, agas bubble 1402 expands dramatically, until an increase in sound-wave pressure triggers a collapse of thegas bubble 1402. As the temperature inside thegas bubble 1402 soars to over 10,000 K, the gas in thebubble 1402 becomes partly ionized, forming aplasma 1404. Finally, recombination of electrons and ions results inlight emission 1406. -
FIG. 30 is a schematic diagram 1500 of acancer cell 1502 illustrating the selective accumulation of asensitizer 908, according to at least one aspect of the present disclosure. In the illustrated example, the 5-ALA sensitizer 908 is systematically administered into thecancer cell 1502 and is absorbed into themitochondria 1504 of thecancer cell 1502. The 5-ALA sensitizer 908 is administered to the patient orally, which puts theheme 1506 biosynthesis pathway into overdrive. The natural feedback mechanism of the patient's body prevents the production of toomuch heme 1506.Heme 1506 will result in lower activity of the aminolevulinic acid synthase (ALAS) enzyme which produces 5-ALA endogenously. By introducing theALA sensitizer 908 exogenously,heme 1506 biosynthesis keeps producing even though the ALAS enzyme is inactivated. As a result,PpIX 1508 accumulates preferentially in many types ofcancer cells 1502 including glioblastoma multiforme (GBM). - The
PpIX 1508 is an active compound and the second to last intermediate product in theheme 1506biosynthesis pathway 1510. The accumulation ofPpIX 1508 in thecancer cell 1502mitochondria 1504 is due to increased uptake of the 5-ALA sensitizer 908 and reduced conversion ofPpIX 1508 intoheme 1506 reduced expression offerrochelatase 1512. - The
PpIX 1508 is a catalyst that converts dissolved molecular oxygen into ROS by absorbing photons.Protoporphyrin IX 1508 is in the same class of molecules as chlorophyll (i.e., porphyrins), and is capable of converting light into chemical energy. -
FIG. 31 is a schematic diagram 1600 of thecancer cell 1502 shown inFIG. 30 undergoing sonodynamic therapy, according to at least one aspect of the present disclosure. Theultrasonic transducer 904 generates an ultrasoundacoustic wave 200 that penetrates thecancer cell 1502 and themitochondria 1504. The ultrasoundacoustic wave 200 produces light 1602 throughcavitation 1606 and a process calledsonoluminescence 1604. The production of light 1602 happens far away from theultrasonic transducer 904. The light 1602 produced throughsonoluminescence 1604 activates thePpIX 1508 to produceROS 1608.Sonoluminescence 1604 can occur anywhere the intensity of the ultrasoundacoustic wave 200 is sufficient, which allows sonodynamic therapy to treat much deeper than photodynamic therapy. TheROS 1608 species cause oxidative stress which results in thecancer cell 1502 undergoing programmed cell death 1610 (apoptosis), which is the same as photodynamic therapy. - The interaction of
acoustic waves 200 with an aqueous medium may result incavitation 1606.Cavitation 1606 involves nucleation, growth, and implosive collapse of gas-filled bubbles, under the appropriate ultrasound conditions. Insonoluminescence 1604,inertial cavitation 1606 involves the growth of gas bubbles to a near resonance size and expanding to a maximum before collapsing violently. The energy released by this implosion results in temperatures of up to 10,000 K and pressures of up to 81 MPa in the surrounding microenvironment. Such extreme temperatures and pressures at the point of implosion create a sono-chemical reactor.Cavitation 1606 generatesROS 1608 in sonodynamic therapy under two mechanisms of action. - One possible mechanism of action is
sonoluminescence 1604. This is process upon which light 1602 is generated upon exposure of thecancer cell 1502 energy produced by theacoustic wave 200. Another possible mechanism of action may be pyrolysis. This is a process whereby localized temperature elevation that accompaniesinertial cavitation 1606 breaks apart thesensitizer 908 generating free radicals that can react with other endogenous substrates to generateROS 1608. AlthoughROS 1608 plays an important role is SDT, in some aspects sonodynamic therapy may be based on sonomechanical mechanisms. This conclusion was based on their observation that HP-sensitized cells can be sensitive to theacoustic wave 200 at intensities that were shown not to induce inertial cavitation. - In various aspects of the present disclosure, sonodynamic therapy may be carried out using one or more than one
sensitizer 908.Such sensitizers 908 used in sonodynamic therapy may be selected from a variety of compounds. These compounds include, without limitation, porphyrins such as Photofrin, protoporphyrin IX precursor, xanthene-basedsensitizers 908 such as Rose Bengal and derivatives thereof, acridine orange, methylene blue, curcumin, hypocrellin, indocyanine green, nanoparticle/microparticle sensitizer conjugates. Additional information on sonodynamic therapy may be found in Treating Cancer With Sonodynamic Therapy: A Review, David Costley et al., pages 107-117, received 17 Oct. 2014, accepted 23 Nov. 2014, published online 13 Jan. 2015, which is herein incorporated by reference in its entirety. In various aspects, the sonodynamic therapy techniques described in this disclosure may be applied to animals as well as humans. In one aspect, the sonodynamic therapy techniques descried in this disclosure may be applied to mammals. In this regard, use of the term “patient” throughout this disclosure is intended to cover humans and animals alike. - In various aspects, the sonodynamic therapy techniques described in this disclosure may be adapted to other parts of the body. These other parts of the body may be accessed through natural orifice (mouth, nasal cavity, anus, vagina) or minimally invasive processes such as intravascular access. The sonodynamic therapy device may be specifically adapted to have a flexible, navigable catheter shaft to reach tumors in specific organs such as liver, stomach, breast, or lungs, for example. The sonodynamic therapy device may be adapted to wrap around the torso or limb and may be employed to treat osteosarcoma into the bone.
- In various aspects, the sonodynamic therapy techniques described in this disclosure may be adapted for use with adjuvant therapies. The disclosed sonodynamic therapy techniques may be employed in other cancer therapies including chemotherapy, immunotherapy, radiotherapy, HIFU/hyperthermia. Further, the disclosed sonodynamic therapy techniques employ additional drugs which increase oxygen in the brain or increase oxygen in a brain tumor to a preferential oxygen concentration to provide an effective sonodynamic therapy. The disclosed sonodynamic therapy techniques may employ a sensitizer which is modified or encapsulated to effectively target a tumor. The disclosed sonodynamic therapy techniques may deliver 0 2 systematically with nose tubes. The disclosed sonodynamic therapy techniques may employ multiple sensitizers in conjunction and may include the introduction of gas bubbles into the tumor to oxygenate the tumor, create more cavitation, and provide a possible contrast mechanism for imaging.
- In various aspects, the sonodynamic therapy techniques described in this disclosure may be adapted for use with ultrasound imaging. The process may include the addition of a contrast agent for ultrasound which goes to the tumor.
- As used herein a processor or processing unit is an electronic circuit which performs operations on some external data source, usually memory or some other data stream. The term is used herein to refer to the central processor (central processing unit) in a system or computer systems (especially systems on a chip (SoCs)) that combine a number of specialized “processors.”
- As used herein, a system on a chip or system on chip (Soc or SOC) is an integrated circuit (also known as an “IC” or “chip”) that integrates all components of a computer or other electronic systems. It may contain digital, analog, mixed-signal, and often radio-frequency functions-all on a single substrate. A Soc integrates a microcontroller (or microprocessor) with advanced peripherals like graphics processing unit (GPU), Wi-Fi module, or coprocessor. A Soc may or may not contain built-in memory.
- As used herein, a microcontroller or controller is a system that integrates a microprocessor with peripheral circuits and memory. A microcontroller (or MCU for microcontroller unit) may be implemented as a small computer on a single integrated circuit It may be similar to a Soc; an Soc may include a microcontroller as one of its components. A microcontroller may contain one or more core processing units (CPUs) along with memory and programmable input/output peripherals. Program memory in the form of Ferroelectric RAM, NOR flash or OTP ROM is also often included on chip, as well as a small amount of RAM. Microcontrollers may be employed for embedded applications, in contrast to the microprocessors used in personal computers or other general purpose applications consisting of various discrete chips.
- As used herein, the term controller or microcontroller may be a stand-alone IC or chip device that interfaces with a peripheral device. This may be a link between two parts of a computer or a controller on an external device that manages the operation of (and connection with) that device.
- Any of the processors or microcontrollers described herein, may be implemented by any single core or multicore processor such as those known under the trade name ARM Cortex by Texas Instruments. In one aspect, the processor may be an LM4F230H5QR ARM Cortex-M4F Processor Core, available from Texas Instruments, for example, comprising on-chip memory of 256 KB single-cycle flash memory, or other non-volatile memory, up to 40 MHz, a prefetch buffer to improve performance above 40 MHz, a 32 KB single-cycle serial random access memory (SRAM), internal read-only memory (ROM) loaded with StellarisWare® software, 2 KB electrically erasable programmable read-only memory (EEPROM), one or more pulse width modulation (PWM) modules, one or more quadrature encoder inputs (QEI) analog, one or more 12-bit Analog-to-Digital Converters (ADC) with 12 analog input channels, details of which are available for the product datasheet
- In one aspect, the processor may comprise a safety controller comprising two controller-based families such as TMS570 and RM4x known under the trade name Hercules ARM Cortex R4, also by Texas Instruments. The safety controller may be configured specifically for IEC 61508 and ISO 26262 safety critical applications, among others, to provide advanced integrated safety features while delivering scalable performance, connectivity, and memory options.
- As used herein, the terms “component,” “system,” “module” and the like can refer to a computer-related entity, either hardware, a combination of hardware and software, software, or software in execution, in addition to electro-mechanical devices. For example, a component may be, but is not limited to being, a process running on a processor, a processor, an object, an executable, a thread of execution, a program, and/or a computer. By way of illustration, both an application running on computer and the computer can be a component. One or more components may reside within a process and/or thread of execution and a component may be localized on one computer and/or distributed between two or more computers. The word “exemplary” is used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein as “exemplar” is not necessarily to be construed as preferred or advantageous over other aspects or designs.
- As used herein, the term control circuit may be any stand alone or combination electronic circuit such as, for example, a processing unit, processor, microcontroller, microcontroller unit, controller, digital signal processor (DSP), programmable gate array (PGA), field PGA (FPGA), programmable logic device (PLD), system on chip (SoC), application specific integrated circuit (ASIC), graphics processing unit (GPU), and the like. According to various aspects, process flow diagrams described herein may be implemented by a digital device such as a control circuit.
- Although the various aspects of the present disclosure describe instruction handling and distribution in the context of execution units and logic circuits, other aspects of the present disclosure can be accomplished by way of data and/or instructions stored on a machine-readable, tangible medium, which when performed by a machine cause the machine to perform functions consistent with at least one aspect. In one aspect, associated functions of the present disclosure are embodied in machine-executable instructions. The instructions can be used to cause a general-purpose or special-purpose processor that is programmed with the instructions to perform the steps of the functions described in the present disclosure. Aspects of the present disclosure may be provided as a computer program product or software which may include a machine or non-transitory computer-readable medium having stored thereon instructions which may be used to program a computer (or other electronic devices) to perform one or more operations according to aspects of the present disclosure. Alternatively, functions according to the present disclosure might be performed by specific hardware components that contain fixed-function logic for performing the functions, or by any combination of programmed computer components and fixed-function hardware components.
- Instructions used to program logic to perform various disclosed aspects can be stored within a memory in the system, such as DRAM, cache, flash memory, or other storage. Furthermore, the instructions can be distributed via a network or by way of other computer readable media. Thus a machine-readable medium may include any mechanism for storing or transmitting information in a form readable by a machine (e.g., a computer), but is not limited to, floppy diskettes, optical disks, Compact Disc, Read-Only Memory (CD-ROMs), and magneto-optical disks, Read-Only Memory (ROMs), Random Access Memory (RAM), Erasable Programmable Read-Only Memory (EPROM), Electrically Erasable Programmable Read-Only Memory (EEPROM), magnetic or optical cards, flash memory, or a tangible, machine-readable storage used in the transmission of information over the Internet via electrical, optical, acoustical or other forms of propagated signals (e.g., carrier waves, infrared signals, digital signals, etc.). Accordingly, the non-transitory computer-readable medium includes any type of tangible machine-readable medium suitable for storing or transmitting electronic instructions or information in a form readable by a machine (e.g., a computer).
- Various examples have been described with reference to certain disclosed aspects. The various aspects are presented for purposes of illustration and not limitation. One skilled in the art will appreciate that various changes, adaptations, and modifications can be made without departing from the scope of the disclosure or the scope of the appended claims.
Claims (20)
1. A method of using focused acoustic waves for non-invasive sonodynamic therapy through a skull to treat cells harboring a sonosensitizer, the method comprising:
acoustically coupling a patient interface to a skin surface of a head of a patient with a brain with tumor cells, the patient interface comprising: an ultrasound transducer array and a cooling system,
wherein the ultrasound transducer array comprises a plurality of ultrasound transducer elements,
wherein the ultrasound transducer array is configured to emit focused acoustic waves through the skull,
wherein the patient interface is configured to acoustically couple the ultrasound transducer array of to the skin surface,
wherein the patient interface is configured for conforming to the skin surface;
driving the ultrasound transducer array with a signal,
wherein the signal is configured to deliver the focused acoustic waves at a frequency with an acoustic intensity in the brain at the tumor cells of the patient; and
circulating a fluid through the cooling system to reduce heat at the head of the patient at the patient interface.
2. The method of claim 1 , further comprising moving the patient interface with respect to the head of the patient.
3. The method of claim 1 , wherein the patient interface comprises at least one of a cap, a rigid shell, and a flexible shell.
4. The method of claim 1 , wherein the non-invasive sonodynamic therapy lasts for 30 minutes to an hour.
5. The method of claim 1 , further comprising administering aminolevulinic acid (ALA) to the patient,
wherein the non-invasive sonodynamic therapy is for use to treat a glioblastoma multiforme (GBM) in the brain,
wherein the sonosensitizer is a porphyrin compound,
wherein the focused acoustic waves are configured to activate the porphyrin compound thereby causing apoptosis of the tumor cells.
6. The method of claim 1 , further comprising administering aminolevulinic acid (ALA) to the patient,
wherein the ultrasound transducer array comprises a grid of elements,
wherein the sonosensitizer is a porphyrin compound, wherein the porphyrin compound becomes cytotoxic upon exposure to the focused acoustic waves,
wherein the acoustic intensity is in a range of 0.1 W/cm2 to 50 W/cm2 to activate the sonosensitizer.
7. A method of using focused acoustic waves for non-invasive sonodynamic therapy through a skull to treat cells harboring a sonosensitizer, the method comprising:
acoustically coupling a non-invasive sonodynamic therapy system to a skin surface of a head of a patient with a brain with tumor cells,
wherein the non-invasive sonodynamic therapy system comprises:
a patient interface, and
an array of ultrasound transducer elements wherein each of the ultrasound transducer elements is configured to emit focused acoustic waves through the skull;
driving the array of ultrasound transducer elements with a signal,
wherein the signal is configured to deliver the focused acoustic waves at a frequency with an acoustic intensity in the brain at the tumor cells of the patient,
wherein the patient interface is configured to acoustically couple the array of ultrasound transducer elements to the skin surface of the head.
8. The method of claim 7 , wherein the patient interface comprises at least one of a cap, a rigid shell and a flexible shell.
9. The method of claim 7 , wherein the non-invasive sonodynamic therapy lasts for 30 minutes to an hour.
10. The method of claim 7 , wherein the signal is a pulse signal to pulse the focused acoustic waves to affect a spatial variation of the acoustic intensity in the brain at the tumor cells of the patient.
11. The method of claim 7 , wherein the focused acoustic waves deliver the non-invasive sonodynamic therapy at the frequency in a range of 20 kHz to 2 MHz to the tumor cells in the brain of the patient to activate the sonosensitizer,
wherein the sonosensitizer becomes cytotoxic upon exposure to the focused acoustic waves,
wherein the sonosensitizer is a porphyrin compound.
12. The method of claim 7 , further comprising administering aminolevulinic acid (ALA) to the patient, wherein the non-invasive sonodynamic therapy is for use to treat a glioblastoma multiforme (GBM) in the brain.
13. A method of using focused acoustic waves for non-invasive sonodynamic therapy through a skull to treat cells harboring a sonosensitizer, the method comprising:
acoustically coupling a patient interface to a skin surface of a head of a patient with a brain with tumor cells, wherein the patient interface comprises an array of ultrasound transducer elements,
wherein each of the ultrasound transducer elements is configured to emit focused acoustic waves through the skull;
driving the array of ultrasound transducer elements with a signal,
wherein the signal is configured to deliver an acoustic intensity in the brain at the tumor cells of the patient.
14. The method of claim 13 , wherein the focused acoustic waves comprise a frequency of 1 MHz.
15. The method of claim 13 , wherein the patient interface comprises at least one of a cap, a rigid shell and a flexible shell.
16. The method of claim 13 , wherein the non-invasive sonodynamic therapy lasts for 30 minutes to an hour.
17. The method of claim 13 ,
wherein the focused acoustic waves comprises a frequency in a range of 20 kHz to 2 MHz,
wherein the sonosensitizer becomes cytotoxic upon exposure to the focused acoustic waves,
wherein the sonosensitizer is a porphyrin compound,
wherein the signal is configured to activate the porphyrin compound thereby causing apoptosis of the tumor cells.
18. The method of claim 14 , further comprising administering microbubbles to the tumor cells,
wherein the sonosensitizer is a porphyrin compound,
wherein the signal is configured to activate the porphyrin compound thereby causing apoptosis of the tumor cells.
19. The method of claim 13 ,
wherein the signal comprises at least one selected from the group consisting of:
a sine wave, a rectangular pulse, and a triangular pulse; and
wherein the sonosensitizer is a porphyrin compound.
20. The method of claim 13 , further comprising administering aminolevulinic acid (ALA) to the patient,
wherein the non-invasive sonodynamic therapy is for use to treat a glioblastoma multiforme (GBM) in the brain,
wherein the sonosensitizer becomes cytotoxic upon exposure to the focused acoustic waves,
wherein the sonosensitizer is a porphyrin compound,
wherein the focused acoustic waves is configured to activate the porphyrin compound to produce a reactive oxygen species (ROS) thereby causing apoptosis of the tumor cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/214,421 US20230338753A1 (en) | 2019-02-13 | 2023-06-26 | Methods of using focused acoustic waves for non-invasive sonodynamic therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962805186P | 2019-02-13 | 2019-02-13 | |
PCT/US2020/017983 WO2020167992A1 (en) | 2019-02-13 | 2020-02-12 | Non-invasive sonodynamic therapy |
US17/399,964 US11730980B2 (en) | 2019-02-13 | 2021-08-11 | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
US18/214,421 US20230338753A1 (en) | 2019-02-13 | 2023-06-26 | Methods of using focused acoustic waves for non-invasive sonodynamic therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/399,964 Continuation US11730980B2 (en) | 2017-08-04 | 2021-08-11 | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230338753A1 true US20230338753A1 (en) | 2023-10-26 |
Family
ID=69771252
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/399,964 Active US11730980B2 (en) | 2017-08-04 | 2021-08-11 | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
US17/400,011 Active US11491353B2 (en) | 2019-02-13 | 2021-08-11 | Zero vergence ultrasound waves for sonodynamic therapy |
US17/399,996 Active US11318332B2 (en) | 2019-02-13 | 2021-08-11 | Methods of treating tumors with pro drugs |
US17/733,868 Active US11617904B2 (en) | 2019-02-13 | 2022-04-29 | Methods of treating tumors with pro drugs |
US17/960,443 Active US11724132B2 (en) | 2019-02-13 | 2022-10-05 | Zero vergence ultrasound waves for sonodynamic therapy |
US18/125,959 Active US11865372B2 (en) | 2019-02-13 | 2023-03-24 | Methods of treating tumors with drugs |
US18/125,971 Pending US20230226379A1 (en) | 2019-02-13 | 2023-03-24 | Methods of treating tumors with pro drugs |
US18/214,372 Active US11872414B2 (en) | 2019-02-13 | 2023-06-26 | Methods of using ultrasound waves for sonodynamic therapy |
US18/214,421 Pending US20230338753A1 (en) | 2019-02-13 | 2023-06-26 | Methods of using focused acoustic waves for non-invasive sonodynamic therapy |
US18/214,386 Pending US20230330441A1 (en) | 2019-02-13 | 2023-06-26 | Methods of producing randomized ultrasound waves for sonodynamic therapy |
US18/540,651 Pending US20240108917A1 (en) | 2019-02-13 | 2023-12-14 | Methods of treating cancer with drugs |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/399,964 Active US11730980B2 (en) | 2017-08-04 | 2021-08-11 | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
US17/400,011 Active US11491353B2 (en) | 2019-02-13 | 2021-08-11 | Zero vergence ultrasound waves for sonodynamic therapy |
US17/399,996 Active US11318332B2 (en) | 2019-02-13 | 2021-08-11 | Methods of treating tumors with pro drugs |
US17/733,868 Active US11617904B2 (en) | 2019-02-13 | 2022-04-29 | Methods of treating tumors with pro drugs |
US17/960,443 Active US11724132B2 (en) | 2019-02-13 | 2022-10-05 | Zero vergence ultrasound waves for sonodynamic therapy |
US18/125,959 Active US11865372B2 (en) | 2019-02-13 | 2023-03-24 | Methods of treating tumors with drugs |
US18/125,971 Pending US20230226379A1 (en) | 2019-02-13 | 2023-03-24 | Methods of treating tumors with pro drugs |
US18/214,372 Active US11872414B2 (en) | 2019-02-13 | 2023-06-26 | Methods of using ultrasound waves for sonodynamic therapy |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/214,386 Pending US20230330441A1 (en) | 2019-02-13 | 2023-06-26 | Methods of producing randomized ultrasound waves for sonodynamic therapy |
US18/540,651 Pending US20240108917A1 (en) | 2019-02-13 | 2023-12-14 | Methods of treating cancer with drugs |
Country Status (8)
Country | Link |
---|---|
US (11) | US11730980B2 (en) |
EP (2) | EP4349401A1 (en) |
KR (1) | KR20210142105A (en) |
CN (1) | CN113677397A (en) |
AU (1) | AU2020221841A1 (en) |
CA (1) | CA3128067A1 (en) |
IL (1) | IL285384A (en) |
WO (1) | WO2020167992A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020221841A1 (en) | 2019-02-13 | 2021-09-09 | Alpheus Medical, Inc. | Non-invasive sonodynamic therapy |
JP2023537219A (en) * | 2020-08-07 | 2023-08-31 | アルフェウス メディカル,インク. | Ultrasound Arrays for Improved Acoustodynamic Therapy to Treat Cancer |
CN112915409A (en) * | 2021-03-01 | 2021-06-08 | 北京儒奥医疗科技有限公司 | Ultrasonic spherical phased control treatment device capable of intelligently targeting and positioning |
WO2023075611A1 (en) * | 2021-10-28 | 2023-05-04 | Reynolds John Noble James | Treatment device |
US20230210493A1 (en) * | 2022-01-04 | 2023-07-06 | University Of Utah Research Foundation | Systems and methods for modulation of deep brain circuits |
WO2023230246A1 (en) * | 2022-05-26 | 2023-11-30 | Alpheus Medical, Inc. | Ultrasound arrays for enhanced tissue therapy |
KR20240019571A (en) * | 2022-08-04 | 2024-02-14 | 엘지전자 주식회사 | Ultrasonic driving device |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050277824A1 (en) * | 2002-08-28 | 2005-12-15 | Jean-Francois Aubry | Non-invasive method of obtaining a pre-determined acoustic wave field in an essentially uniform medium which is concealed by a bone barrier, imaging method and device for carrying out said methods |
US20090062724A1 (en) * | 2007-08-31 | 2009-03-05 | Rixen Chen | System and apparatus for sonodynamic therapy |
US20170095557A1 (en) * | 2015-10-01 | 2017-04-06 | Wei Fang | Dvdms sensitizer for cancer sonodynamic therapy |
US20180177491A1 (en) * | 2016-12-22 | 2018-06-28 | Sunnybrook Research Institute | Systems and methods for performing transcranial ultrasound therapeutic and imaging procedures |
US20180207447A1 (en) * | 2017-01-24 | 2018-07-26 | National Yang-Ming University | Therapy for glioblastoma multiforme |
US20180344872A1 (en) * | 2015-11-23 | 2018-12-06 | University Of Ulster | Microbubble-chemotherapeutic agent complex for sonodynamic therapy |
US11730980B2 (en) * | 2019-02-13 | 2023-08-22 | Alpheus Medical, Inc. | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
US20230338751A1 (en) * | 2017-08-04 | 2023-10-26 | Alpheus Medical, Inc. | Methods of using planar or defocused acoustic waves for non-invasive sonodynamic therapy |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576177A (en) | 1983-02-18 | 1986-03-18 | Webster Wilton W Jr | Catheter for removing arteriosclerotic plaque |
JPS6053131A (en) | 1983-08-31 | 1985-03-26 | 富士通株式会社 | Ultrasonic air bubble generating system |
US4735201A (en) | 1986-01-30 | 1988-04-05 | The Beth Israel Hospital Association | Optical fiber with detachable metallic tip for intravascular laser coagulation of arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US4875487A (en) * | 1986-05-02 | 1989-10-24 | Varian Associates, Inc. | Compressional wave hyperthermia treating method and apparatus |
US4807633A (en) | 1986-05-21 | 1989-02-28 | Indianapolis Center For Advanced Research | Non-invasive tissue thermometry system and method |
JPH05172Y2 (en) | 1986-06-13 | 1993-01-06 | ||
DE69111079T2 (en) | 1990-12-10 | 1995-11-02 | Howmedica | Device for the interstitial application of laser light. |
DE4228084C1 (en) | 1992-08-24 | 1993-12-23 | Suedzucker Ag | Process for the preparation of N-acyl derivatives of 5-aminolevulinic acid and the hydrochloride of free acid |
US5738635A (en) | 1993-01-22 | 1998-04-14 | Technomed Medical Systems | Adjustable focusing therapeutic apparatus with no secondary focusing |
US5445608A (en) | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
EP0718405B1 (en) | 1994-12-20 | 2002-10-02 | Cosmo Research Institute | 5-Aminolevulinic acid producing microorganism |
US6176842B1 (en) | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
AU5312496A (en) | 1995-03-16 | 1996-10-02 | Medtronic Ps Medical | Partially disposable surgical imaging assembly |
US5558092A (en) | 1995-06-06 | 1996-09-24 | Imarx Pharmaceutical Corp. | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
GB9710049D0 (en) | 1997-05-19 | 1997-07-09 | Nycomed Imaging As | Method |
FR2764516B1 (en) * | 1997-06-11 | 1999-09-03 | Inst Nat Sante Rech Med | ULTRASONIC INTRATISSULAIRE APPLICATOR FOR HYPERTHERMIA |
US6231516B1 (en) | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
EP1198213B1 (en) | 1999-06-25 | 2010-06-09 | Vahid Saadat | Apparatus for treating tissue |
US20030114434A1 (en) | 1999-08-31 | 2003-06-19 | James Chen | Extended duration light activated cancer therapy |
US6576257B1 (en) | 1999-10-12 | 2003-06-10 | Yehuda Yarmut | Targeted drug activation |
US7790144B2 (en) | 2000-01-18 | 2010-09-07 | Mallinckrodt Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
US7198778B2 (en) | 2000-01-18 | 2007-04-03 | Mallinckrodt Inc. | Tumor-targeted optical contrast agents |
JP3565758B2 (en) * | 2000-03-09 | 2004-09-15 | 株式会社日立製作所 | Sensitizer for tumor treatment |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US6733450B1 (en) | 2000-07-27 | 2004-05-11 | Texas Systems, Board Of Regents | Therapeutic methods and apparatus for use of sonication to enhance perfusion of tissue |
US6622049B2 (en) | 2000-10-16 | 2003-09-16 | Remon Medical Technologies Ltd. | Miniature implantable illuminator for photodynamic therapy |
US6575922B1 (en) * | 2000-10-17 | 2003-06-10 | Walnut Technologies | Ultrasound signal and temperature monitoring during sono-thrombolysis therapy |
FR2815717B1 (en) | 2000-10-20 | 2003-01-10 | Centre Nat Rech Scient | NON-INVASIVE METHOD AND DEVICE FOR FOCUSING ACOUSTIC WAVES |
US8123789B2 (en) | 2002-04-29 | 2012-02-28 | Rohit Khanna | Central nervous system cooling catheter |
US7498029B2 (en) | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
AU2002343457A1 (en) | 2001-09-28 | 2003-04-07 | Biovalve Technologies, Inc. | Switchable microneedle arrays and systems and methods relating to same |
US6599246B1 (en) * | 2002-01-25 | 2003-07-29 | Kenneth W. Coffey | Apparatus and method for substantially stationary transducer therapeutic ultrasound treatment |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
US20040049134A1 (en) * | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
US20040171601A1 (en) | 2002-07-31 | 2004-09-02 | Dai Fukumura | Photodynamic and sonodynamic therapy |
JP3842188B2 (en) | 2002-08-28 | 2006-11-08 | 株式会社日立製作所 | Ultrasonic therapy device |
FR2849781B1 (en) | 2003-01-14 | 2005-03-25 | Edap S A | THERAPY PROBE |
US8353853B1 (en) * | 2003-01-24 | 2013-01-15 | Boston Scientific Scimed, Inc. | Encephalic insonication |
WO2004082736A2 (en) | 2003-03-14 | 2004-09-30 | Light Sciences Corporation | Light generating device to intravascular use |
US7175599B2 (en) * | 2003-04-17 | 2007-02-13 | Brigham And Women's Hospital, Inc. | Shear mode diagnostic ultrasound |
US7850946B2 (en) | 2003-05-31 | 2010-12-14 | Washington University In St. Louis | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
JP4398813B2 (en) | 2003-07-18 | 2010-01-13 | ヤーマン株式会社 | Skin care equipment |
US7044960B2 (en) * | 2003-09-17 | 2006-05-16 | Medivance Incorporated | Method and apparatus for providing non-invasive ultrasound heating of the preoptic anterior hypothalamus |
JP2005152093A (en) | 2003-11-21 | 2005-06-16 | Terumo Corp | Catheter |
US20050124897A1 (en) * | 2003-12-03 | 2005-06-09 | Scimed Life Systems, Inc. | Apparatus and methods for delivering acoustic energy to body tissue |
CN101885692B (en) | 2004-03-30 | 2011-11-02 | 克斯莫石油株式会社 | 5-aminolevulinic acid phosphate salt, process for producing the same and use thereof |
CA2573744A1 (en) | 2004-07-22 | 2006-03-02 | Ondine International Ltd. | Sonophotodynamic therapy for dental applications |
WO2006021651A1 (en) | 2004-07-23 | 2006-03-02 | Inserm | Ultrasound treating device and method |
US8409099B2 (en) | 2004-08-26 | 2013-04-02 | Insightec Ltd. | Focused ultrasound system for surrounding a body tissue mass and treatment method |
GB0510470D0 (en) | 2005-05-23 | 2005-06-29 | Qinetiq Ltd | Coded aperture imaging system |
CA2610561A1 (en) | 2005-06-02 | 2006-12-07 | Cancercure Technology As | Ultrasound treatment system |
WO2006134754A1 (en) | 2005-06-13 | 2006-12-21 | Takayuki Saguchi | Ultrasonic wave radiator for treatment |
JP4369907B2 (en) * | 2005-07-01 | 2009-11-25 | 株式会社日立製作所 | Sonochemical treatment equipment |
US8506931B2 (en) | 2005-08-10 | 2013-08-13 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
EP1834646B1 (en) | 2005-10-26 | 2016-06-22 | Toto Ltd. | Ultrasonic cancer therapy accelerator and cytotoxic agent |
US8548562B2 (en) | 2006-04-04 | 2013-10-01 | John Trachtenberg | System and method of guided treatment within malignant prostate tissue |
US8057464B2 (en) | 2006-05-03 | 2011-11-15 | Light Sciences Oncology, Inc. | Light transmission system for photoreactive therapy |
KR100796450B1 (en) | 2006-06-29 | 2008-01-22 | 전남대학교산학협력단 | Unsaturated alkyl esters of 5-aminolevulinic acid, their preparation and their use |
US8070682B2 (en) | 2006-07-19 | 2011-12-06 | The University Of Connecticut | Method and apparatus for medical imaging using combined near-infrared optical tomography, fluorescent tomography and ultrasound |
US7652410B2 (en) | 2006-08-01 | 2010-01-26 | Insightec Ltd | Ultrasound transducer with non-uniform elements |
US20100106229A1 (en) * | 2006-09-08 | 2010-04-29 | Adroit Medical Systems, Inc. | Thermal skull pads for coolant system |
US9313423B2 (en) | 2006-10-06 | 2016-04-12 | California Institute Of Technology | Deep tissue focal fluorescence imaging with digitally time-reversed ultrasound-encoded light |
JP2010511720A (en) | 2006-12-05 | 2010-04-15 | ユニバーシティー オブ フロリダ リサーチ ファウンデイション インコーポレイテッド | Systems and methods based on radiation-induced heating or ignition of functionalized fullerenes |
US8465533B2 (en) | 2007-03-06 | 2013-06-18 | Novocure Limited | Treating cancer using electromagnetic fields in combination with photodynamic therapy |
US8910638B2 (en) | 2007-05-09 | 2014-12-16 | Massachusetts Institute Of Technology | Methods and apparatus for high-throughput neural screening |
EP2170181B1 (en) | 2007-06-22 | 2014-04-16 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
US20090099483A1 (en) | 2007-10-11 | 2009-04-16 | Andrey Rybyanets | Apparatus and method for ultrasound treatment |
GB0723124D0 (en) | 2007-11-26 | 2008-01-02 | Univ Leuven Kath | Targeted radiotherapy |
EP2231105A1 (en) | 2007-12-14 | 2010-09-29 | Photoderma SA | Novel compounds useful in therapeutic and cosmetic methods |
KR100975595B1 (en) | 2008-01-15 | 2010-08-13 | 전남대학교산학협력단 | Carried growth-plate stimulation type growing acelerating device including 2 phase ultrasonic oscillation generator and LED device |
CN101925382A (en) | 2008-01-28 | 2010-12-22 | 耶达研究及发展有限公司 | Endoscopic imaging photodynamic therapy system and methods of use |
US8206326B2 (en) | 2008-03-04 | 2012-06-26 | Sound Surgical Technologies, Llc | Combination ultrasound-phototherapy transducer |
WO2010009106A1 (en) | 2008-07-14 | 2010-01-21 | Bourke Frederic A Jr | Advanced methods and systems for treating cell proliferation disorders |
GB0900461D0 (en) | 2009-01-12 | 2009-02-11 | Photocure Asa | Photodynamic therapy device |
US8771741B2 (en) | 2009-01-23 | 2014-07-08 | The Penn State Research Foundation | In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles |
US20100262115A1 (en) | 2009-04-07 | 2010-10-14 | Intelligentnano Inc. | Nanoparticles for cancer sonodynamic and photodynamic therapy |
WO2010142457A1 (en) | 2009-06-11 | 2010-12-16 | Photocure Asa | Semi-solid compositions and pharmaceutical products |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
WO2011044671A1 (en) | 2009-10-16 | 2011-04-21 | University Health Network | Porphyrin nanovesicles |
EP2496525A4 (en) | 2009-11-03 | 2013-05-29 | Produitson Inc | Method and apparatus for controlling the propagation of cyanobacteria in a body of water |
WO2011057028A1 (en) * | 2009-11-04 | 2011-05-12 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Devices and methods for modulating brain activity |
BR112012016312A2 (en) | 2009-12-31 | 2016-08-23 | Zetroz Llc | "transducer, and method for manufacturing a low profile ultrasonic transducer." |
CN102233159A (en) * | 2010-05-06 | 2011-11-09 | 高春平 | Focused ultrasonic noninvasive sound powered tumor therapy system |
US9409036B2 (en) | 2010-07-19 | 2016-08-09 | Wake Forest University Health Sciences | Implantable connector systems having magnetic portions thereon and related methods |
US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
WO2012029771A1 (en) | 2010-08-30 | 2012-03-08 | 学校法人福岡大学 | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation using tumor proliferation inhibitor and low-intensity pulsed ultrasound |
WO2012035747A1 (en) | 2010-09-14 | 2012-03-22 | 学校法人東京農業大学 | Cancer heat therapy-enhancing agent |
EP2627358B1 (en) | 2010-10-14 | 2024-03-27 | Tagworks Pharmaceuticals B.V. | Pretargeting kit, method and agents used therein |
JP6351974B2 (en) | 2011-02-14 | 2018-07-04 | メルク パテント ゲーエムベーハー | Devices and methods for treatment of cells and cellular tissues |
US9669203B2 (en) * | 2011-03-01 | 2017-06-06 | University Of Cincinnati | Methods of enhancing delivery of drugs using ultrasonic waves and systems for performing the same |
US10702244B2 (en) | 2011-06-29 | 2020-07-07 | Sunnybrook Research Institute | System and method for controlling focused ultrasound treatment |
US9371555B2 (en) | 2012-06-01 | 2016-06-21 | Concordia Laboratories Inc. | Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin |
US9493810B2 (en) | 2012-06-07 | 2016-11-15 | Pioma, Inc. | 5-ALA for detection of brain tumors |
CN108113762A (en) | 2012-06-27 | 2018-06-05 | 曼特瑞斯医药有限责任公司 | The image guided therapy of tissue |
CN104661994B (en) | 2012-08-03 | 2017-08-08 | 光治疗Asa公司 | Compound |
US11167154B2 (en) * | 2012-08-22 | 2021-11-09 | Medtronic, Inc. | Ultrasound diagnostic and therapy management system and associated method |
CN102885648B (en) | 2012-08-29 | 2015-03-18 | 中国人民解放军第三军医大学第一附属医院 | Sympathetic nerve denervation ablation catheter system for kidneys |
WO2014164363A1 (en) | 2013-03-09 | 2014-10-09 | Kona Medical, Inc. | Transducers, systems, and manufacturing techniques for focused ultrasound therapies |
US9963724B2 (en) | 2013-03-22 | 2018-05-08 | Neo Ala Co., Ltd. | Method for producing 5-aminolevulinic acid or salt thereof |
GB201306369D0 (en) | 2013-04-09 | 2013-05-22 | Photocure As | Irradiation device |
JP6450752B2 (en) | 2013-06-28 | 2019-01-09 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Transducer placement and alignment for image-guided ultrasonic thrombolysis |
CN103395654B (en) | 2013-07-12 | 2016-03-02 | 广州广电运通金融电子股份有限公司 | A kind of bank note storage means and equipment |
CA2935743A1 (en) | 2014-01-04 | 2015-07-09 | Vijay Agarwal | Device and method for use of photodynamic therapy |
US9492121B2 (en) | 2014-03-18 | 2016-11-15 | Monteris Medical Corporation | Image-guided therapy of a tissue |
KR101708754B1 (en) | 2014-11-04 | 2017-02-21 | 서강대학교산학협력단 | A method for continuous production of 5-aminolevulinic acid by photosynthetic membrane vesicle |
US10456603B2 (en) | 2014-12-10 | 2019-10-29 | Insightec, Ltd. | Systems and methods for optimizing transskull acoustic treatment |
US20180001114A1 (en) | 2014-12-15 | 2018-01-04 | Vesselon, Inc. | Automated ultrasound apparatus and method for noninvasive vessel recanalization treatment and monitoring |
CA2970514C (en) * | 2014-12-19 | 2023-09-12 | Universite Pierre Et Marie Curie (Paris 6) | Implantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device |
US20160243381A1 (en) * | 2015-02-20 | 2016-08-25 | Medtronic, Inc. | Systems and techniques for ultrasound neuroprotection |
US20180049762A1 (en) | 2015-03-30 | 2018-02-22 | Koninklijke Philips N.V. | Ultrasonic transducer array for sonothrombolysis treatment and monitoring |
WO2017087775A1 (en) | 2015-11-20 | 2017-05-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Phase change nanodroplet conjugates for targeted delivery |
CN112010772A (en) | 2016-01-26 | 2020-12-01 | 赵鸣 | Salt compound of 5-aminolevulinic acid and derivative thereof and application |
AU2017222925B2 (en) | 2016-02-23 | 2021-11-04 | Sunnybrook Research Institute | Patient-specific headset for diagnostic and therapeutic transcranial procedures |
US11534630B2 (en) | 2016-08-01 | 2022-12-27 | Cordance Medical Inc. | Ultrasound guided opening of blood-brain barrier |
WO2018035256A1 (en) | 2016-08-16 | 2018-02-22 | Bhaskar Ramamurthy | Systems and methods for ultrasound review and imaging |
US20190030375A1 (en) * | 2017-02-23 | 2019-01-31 | Oron Zachar | Transcranial ultrasound focusing |
US20220126120A1 (en) * | 2017-02-23 | 2022-04-28 | Oron Zachar | Transcranial ultrasound focusing |
WO2018164755A1 (en) | 2017-03-06 | 2018-09-13 | Neural Analytics, Inc. | Headset system |
US20190009111A1 (en) | 2017-06-08 | 2019-01-10 | Gunnar Myhr | Non-invasive and optimized system for the rejuvenation and removal of wrinkles of the skin |
US10555861B2 (en) | 2017-08-11 | 2020-02-11 | Neural Analytics, Inc. | Dynamic headset apparatus |
WO2019050963A1 (en) | 2017-09-05 | 2019-03-14 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Sonodynamic therapy using microbubbles and pulsed wave ultrasound methods and systems |
WO2019059027A1 (en) | 2017-09-19 | 2019-03-28 | ネオファーマジャパン株式会社 | Composition for order decapoda, including 5-aminolevulinic acid |
EP3749207B1 (en) | 2018-02-07 | 2023-07-12 | Cimon Medical AS | Ultrasound blood-flow monitoring |
CN112789003A (en) | 2018-08-08 | 2021-05-11 | 颅骨切除术公司 | Treatment of tissue with sensitizers and light and/or sound |
WO2020069084A1 (en) | 2018-09-28 | 2020-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Detection, localization, and/or suppression of neural activity using acoustic waves and/or ultrasound |
WO2020217472A1 (en) | 2019-04-26 | 2020-10-29 | 株式会社Jimro | Medicinal composition for preventing or treating treatment-resistant cancer |
WO2020243319A1 (en) | 2019-05-29 | 2020-12-03 | Sonalasense, Inc. | Sonosensitization |
CN211536251U (en) | 2019-11-11 | 2020-09-22 | 刘继伟 | Tumor acoustic dynamic treatment device |
AU2021212658A1 (en) | 2020-01-27 | 2022-08-25 | Cordance Medical Inc. | Ultrasound transducer assembly |
JP2023537219A (en) | 2020-08-07 | 2023-08-31 | アルフェウス メディカル,インク. | Ultrasound Arrays for Improved Acoustodynamic Therapy to Treat Cancer |
-
2020
- 2020-02-12 AU AU2020221841A patent/AU2020221841A1/en active Pending
- 2020-02-12 EP EP23210189.9A patent/EP4349401A1/en active Pending
- 2020-02-12 WO PCT/US2020/017983 patent/WO2020167992A1/en unknown
- 2020-02-12 EP EP20710018.1A patent/EP3924046B1/en active Active
- 2020-02-12 CN CN202080027197.1A patent/CN113677397A/en active Pending
- 2020-02-12 CA CA3128067A patent/CA3128067A1/en active Pending
- 2020-02-12 KR KR1020217028862A patent/KR20210142105A/en unknown
-
2021
- 2021-08-04 IL IL285384A patent/IL285384A/en unknown
- 2021-08-11 US US17/399,964 patent/US11730980B2/en active Active
- 2021-08-11 US US17/400,011 patent/US11491353B2/en active Active
- 2021-08-11 US US17/399,996 patent/US11318332B2/en active Active
-
2022
- 2022-04-29 US US17/733,868 patent/US11617904B2/en active Active
- 2022-10-05 US US17/960,443 patent/US11724132B2/en active Active
-
2023
- 2023-03-24 US US18/125,959 patent/US11865372B2/en active Active
- 2023-03-24 US US18/125,971 patent/US20230226379A1/en active Pending
- 2023-06-26 US US18/214,372 patent/US11872414B2/en active Active
- 2023-06-26 US US18/214,421 patent/US20230338753A1/en active Pending
- 2023-06-26 US US18/214,386 patent/US20230330441A1/en active Pending
- 2023-12-14 US US18/540,651 patent/US20240108917A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050277824A1 (en) * | 2002-08-28 | 2005-12-15 | Jean-Francois Aubry | Non-invasive method of obtaining a pre-determined acoustic wave field in an essentially uniform medium which is concealed by a bone barrier, imaging method and device for carrying out said methods |
US20090062724A1 (en) * | 2007-08-31 | 2009-03-05 | Rixen Chen | System and apparatus for sonodynamic therapy |
US20170095557A1 (en) * | 2015-10-01 | 2017-04-06 | Wei Fang | Dvdms sensitizer for cancer sonodynamic therapy |
US20180344872A1 (en) * | 2015-11-23 | 2018-12-06 | University Of Ulster | Microbubble-chemotherapeutic agent complex for sonodynamic therapy |
US20180177491A1 (en) * | 2016-12-22 | 2018-06-28 | Sunnybrook Research Institute | Systems and methods for performing transcranial ultrasound therapeutic and imaging procedures |
US20180207447A1 (en) * | 2017-01-24 | 2018-07-26 | National Yang-Ming University | Therapy for glioblastoma multiforme |
US20230338751A1 (en) * | 2017-08-04 | 2023-10-26 | Alpheus Medical, Inc. | Methods of using planar or defocused acoustic waves for non-invasive sonodynamic therapy |
US11730980B2 (en) * | 2019-02-13 | 2023-08-22 | Alpheus Medical, Inc. | Methods of using planar acoustic waves for non-invasive sonodynamic therapy |
Non-Patent Citations (1)
Title |
---|
Galkin, "The Use of Transcranial Focused Ultrasound in CNS Diseases", January 2016, Problems of Neurosurgery, pages 1-108 (Year: 2016) * |
Also Published As
Publication number | Publication date |
---|---|
US20210369843A1 (en) | 2021-12-02 |
US20240108917A1 (en) | 2024-04-04 |
CA3128067A1 (en) | 2020-08-20 |
JP2022524297A (en) | 2022-05-02 |
US20230226379A1 (en) | 2023-07-20 |
US20230037342A1 (en) | 2023-02-09 |
EP4349401A1 (en) | 2024-04-10 |
IL285384A (en) | 2021-09-30 |
EP3924046A1 (en) | 2021-12-22 |
US20210370102A1 (en) | 2021-12-02 |
EP3924046B1 (en) | 2023-11-22 |
US20230330441A1 (en) | 2023-10-19 |
US20220257984A1 (en) | 2022-08-18 |
AU2020221841A1 (en) | 2021-09-09 |
CN113677397A (en) | 2021-11-19 |
US20230277877A1 (en) | 2023-09-07 |
US20210370103A1 (en) | 2021-12-02 |
US11872414B2 (en) | 2024-01-16 |
US20230338752A1 (en) | 2023-10-26 |
US11491353B2 (en) | 2022-11-08 |
US11617904B2 (en) | 2023-04-04 |
US11724132B2 (en) | 2023-08-15 |
KR20210142105A (en) | 2021-11-24 |
WO2020167992A1 (en) | 2020-08-20 |
US11730980B2 (en) | 2023-08-22 |
US11865372B2 (en) | 2024-01-09 |
US11318332B2 (en) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11872414B2 (en) | Methods of using ultrasound waves for sonodynamic therapy | |
US20230338751A1 (en) | Methods of using planar or defocused acoustic waves for non-invasive sonodynamic therapy | |
Hynynen et al. | Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy | |
Diederich et al. | Ultrasound technology for hyperthermia | |
US20230330443A1 (en) | Ultrasound arrays for enhanced sonodynamic therapy for treating cancer | |
EP3099379A1 (en) | Therapeutic ultrasound apparatus and method | |
JP7474773B2 (en) | Non-invasive sonodynamic therapy | |
Seip et al. | Comparison of split-beam transducer geometries and excitation configurations for transrectal prostate HIFU treatments | |
Hutchinson et al. | Evaluation of an aperiodic phased array for prostate thermal therapies | |
WO2023230246A1 (en) | Ultrasound arrays for enhanced tissue therapy | |
Hosseinzadeh et al. | Numerical simulation of the 3 dimensional heated necrosis element under HIFU transducer | |
JP2014217560A (en) | No sensitization-type radiation cancer treatment system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |